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ABSTRACT 
Xuezheng Sun: Parity, Obesity and Breast Cancer Survival: Does Intrinsic Subtype Modify 
Outcomes?  
(Under the direction of Melissa Troester) 
Purpose: Parity and obesity have shown distinct associations with the breast cancer risk 
by intrinsic subtype.  Little is known whether their influence on prognosis also varies by intrinsic 
subtype, although their general prognostic associations have been reported previously.  
Methods: Study subjects were 1,140 invasive breast cancer patients from the phases I and II of 
the population-based Carolina Breast Cancer Study (CBCS), with tissue blocks available for 
subtyping using immunohistochemical markers.  Parity was measured by number of full-term 
birth and time since last birth.  Obesity was measured by body mass index (BMI) and waist hip 
ratio (WHR).  Vital status was determined using the National Death Index.  The association of 
exposures with breast cancer (BC)-specific and overall survival was assessed using the Cox 
proportional hazards model.  Results:  During the follow-up (median =13.5 years), 450 patients 
died, with 61% due to breast cancer (n=276).  For obesity, WHR, but not BMI, was associated 
with an increased risk of all-cause mortality (≥ 0.84 vs. <0.77, adjusted hazard ratio (HR) = 1.50, 
95% confidence interval (CI) =1.11-2.05), independent of age, race, adjusted lifestyle and 
socioeconomic factors.  According to intrinsic subtypes, high BMI (≥30 kg/m2) was an 
independent factor for all-cause mortality (adjusted HR=2.25, 95% CI=1.14-4.46, <0.25 kg/m2 as 
reference) among patients with basal-like tumors, while high WHR (≥0.84) was associated with 
poor overall survival (adjusted HR=1.75, 95% CI=1.20-2.56, <0.77 as reference) among patients 
with luminal tumors.  For parity, both high parity (3+ births) and recent birth (< 5 years before 
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diagnosis) were associated with BC-specific mortality (parity: adjusted HR=1.76, 95% CI=1.13-
2.73; birth recency: adjusted HR=1.90, 95% CI=1.10-3.34), with stronger effect observed in 
luminal tumors than basal-like tumors.  The subtype-specific prognostic associations of parity 
and obesity were suggested to vary by follow-up period (greater HRs detected in patients 
surviving ≥5 years), but not by race or menopause.  Conclusions: Our study suggests the 
influence of obesity and parity on breast cancer prognosis may vary by intrinsic subtype. These 
results may contribute to a better understanding of how pregnancy and obesity influence the 
natural history of different breast cancer subtype, and help tailor treatment and optimize 
intervention strategies.  
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 CHAPTER 1: BACKGROUND 
Despite many advances in screening, prevention and novel treatment, breast cancer remains 
the most frequent cancer and the second leading cause of cancer mortality in women (1, 2).  
Approximately 232,340 new cases of invasive breast cancer and 39,620 breast cancer deaths are 
expected to occur among US women in 2013 (3, 4).  The burden of the disease is likely to rise 
over the next 20 years due to the increasing population of older adults and minorities, with 
invasive breast cancer expected to reach 294,000 in 2030 (5).  The increasing public health 
burden underpins the importance of breast cancer research.  The establishment of breast cancer 
heterogeneity, namely intrinsic subtype using global gene expression techniques, suggests the 
need to reweigh epidemiological findings in this new context.  Specifically, evaluating the 
influence of breast cancer heterogeneity on the association of breast cancer risk factors with 
breast cancer prognosis would provide novel insights into the previously mixed observations on 
these associations.   
1.1. Heterogeneity of breast cancer 
1.1.1. Biological heterogeneity 
Breast cancer has long been recognized as a heterogeneous disease.  Previously, this 
complexity was mainly characterized by hormone receptors, including estrogen receptor (ER) 
and progesterone receptor (PR).  This classification reflects etiological heterogeneity, which also 
has been supported by epidemiologic data.  Distinct associations with risk factors, such as age (6, 
7), race/ethnicity (8, 9), reproductive factors (7, 10, 11), anthropometric factors (12, 13), and 
2 
 
lifestyle factors (14), across subtypes defined by hormone receptor status have been observed in 
many studies across different populations.  The differences by hormone receptor status are also 
observed in screening mammography detection (15), clinicopathological characteristics (16, 17), 
treatment availability (18, 19), and prognosis (19, 20).  Although hormone receptors provide a 
rough picture for breast cancer heterogeneity, the intra-category heterogeneity has been 
recognized as tumors with the same hormone receptor status can respond differently to therapy, 
resulting in different outcomes.  In response to this recognition, several additional biomarkers 
(such as P53, Ki67, and Her2) have been developed to capture heterogeneity from proliferation, 
apoptosis, migration, and other aspects of breast cancer biology not captured by hormone 
receptor status (21-23).  Previous analyses usually describe breast cancer heterogeneity using 
individual biomarkers.  The mechanism of breast cancer heterogeneity is complex, involving 
distinct cellular origins, genetic and epigenetic alterations, and paracrine signals from 
surrounding cells (24).  Considering the complex etiology of tumor subtypes, an individual 
biomarker is obviously insufficient to portray distinct tumor phenotypes.  Recent advances in 
new techniques (such as cDNA microarray) have allowed a more comprehensive profiling of 
breast cancers across thousands of genomic biomarkers.    
Discovery of intrinsic breast cancer subtype 
In 2000, using cDNA microarray and hierarchical clustering, Perou and colleagues 
categorized breast cancer into five intrinsic subtypes based on differences in molecular patterns: 
luminal A, luminal B, Her2-enriched, basal-like, and normal-like (25).  Later, the robustness and 
universality of this new taxonomy was confirmed in larger, multi-ethnic populations using 
different microarray platforms and across different breast cancer histological types (26-32).  
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Luminal A and luminal B tumors are predominately ER positive and express genes similar 
to luminal mammary epithelial cells.  In contrast, basal-like tumors are predominately ER 
negative and express genes associated with normal myoepithelial cells of the outer layer of the 
breast duct (24, 26, 33).  Her2-enriched tumors are characterized by high expression of several 
genes in the ERBB2 amplicon (neu/HER2) (24).  Normal-like tumors show high expression 
levels of many genes known to be expressed by adipose tissue and other non-epithelial genes.  
Some researchers suggested that normal-like tumors may represent tumor samples contaminated 
by normal tissue (34).  Besides differences in expression of biomarkers of cellular origin, 
intrinsic subtypes demonstrate differences in proliferation.  Compared to basal-like and luminal 
B tumors, proliferation rates and expression of proliferation-associated genes were lower for 
luminal A and lowest among Her2-enriched tumors (24, 26, 33, 35).  In addition, the rate of 
TP53 mutation was lower in luminal A tumors, and BRCA1 mutation is more frequent in basal-
like tumors than other subtypes (33).  In recent studies, more genetic and genomic differences 
(such as androgen receptor, GATA3, FOXA1, keratin 18, and PI3KCA) (36) have been 
characterized for each breast cancer subtype, further underscoring their distinction in their 
biological characteristics.  
Pathogenesis by intrinsic subtype 
As a reflection of the underlying biology and genomics, intrinsic types vary considerably in 
their natural disease history.  Compared to luminal A tumors, basal-like tumors are more likely 
to be invasive ductal cancers with high-grade/poor differentiation (25, 37-46).  They also have 
high proliferative index, high nuclear/cytoplasmic ratio, pushing margins of invasion, central 
necrosis, and lymphocyte-rich stroma (39, 47, 48).  In contrast, luminal tumors (both luminal A 
and B) tend to be well-differentiated with lower nuclear grade.  In studies comparing intrinsic 
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subtypes of invasive breast tumor and ductal carcinoma in situ (DCIS), luminal A tumors are 
more prevalent than DCIS (49-52).  Regarding tumor size and axillary lymph node involvement, 
findings are inconsistent, with some studies showing larger tumors and higher rates of lymph 
node positivity in basal-like tumors (27, 42, 53), but others finding no differences (38, 41).  
Similar to basal-like tumors, Her2-enriched tumors also demonstrate higher grade and larger size 
than luminal tumors (43, 44, 46), although their progression is thought to be slow (54). 
Classification by IHC biomarker  
Originally, subtype classification was based on cDNA microarray techniques, which 
require frozen tissue for RNA extraction and analysis.  Since frozen tissues are not routinely 
available in clinical practice and epidemiological studies, methods are needed for subtyping 
tumors using formalin-fixed paraffin embedded tissues.  To this end, immunohistochemistry 
(IHC) classification protocols have been developed and used in the vast majority of published 
reports.  The most frequently used IHC classification criteria were developed by Nielsen and 
colleagues (55).  According to this schema, luminal A tumors are immunohistochemically 
identified by the expression of ER, the presence or absence of PR, and the absence of Her2 
expression.  Luminal B tumors are hormone receptor positive (ER positive and/or PR positive), 
but differ from luminal A tumors in that they are positive for expression of Her2.  Her2-positive 
tumors are defined by the lack of expression of hormone receptors and the presence of HER2 
tyrosine kinase receptor.  Basal-like tumors are defined by the lack of ER, PR and Her2, but the 
expression of either epidermal growth factor receptor (EGFR) or cytokeratin (CK)5/6+.  This 
categorization approach was revised recently by the St. Galen International Expert Consensus 
panel, with emphasis on distinguishing between luminal A and luminal B tumors (56, 57).  By 
the newly proposed IHC-based definition, luminal A tumors are ER-positive, Her2-negative, are 
5 
 
Ki-67-positive in less than 14% of cells, and PR-positive in more than 20% of cells.  Luminal B 
tumors are either ER-positive and PR-positive and Her2-positive, or ER-positive and Her2-
negative and either Ki-67≥14% or PR≥20% (35, 57).  Of note, although representing a 
convenient approximation, subtypes defined by IHC biomarkers are similar, but not identical, to 
intrinsic subtypes defined by cDNA microarray.     
Due to similarities in these definitions and the availability of ER, PR, and Her2 status in 
clinical records, triple negative breast cancer (TNBC) and basal-like breast cancer (BLBC) have 
been used interchangeably in some papers.  However, they do not completely overlap, with 
discordance between 20-30% (58, 59).  TNBC is more biologically heterogeneous, including all 
the intrinsic subtypes, with BLBC accounting for about 70% (60).  As the intrinsic subtype 
definition had superior prognostic value than the three-biomarker classification, intrinsic subtype 
is considered more precise at describing the intrinsic biological differences in breast cancer (60, 
61, 61-65).  In this proposal, the literature review focused on studies using intrinsic subtype, but 
still included reports on TNBC considering the large amount of literature.  
1.1.2. Distinct epidemiological risk factor profile by intrinsic subtype 
The heterogeneity in biological and histopathological tumor features suggests distinct 
etiologies, which has been confirmed in epidemiologic studies of risk factors.  The risk factors 
that have been evaluated for associations with intrinsic subtype include age, anthropometric 
factors, reproductive factors, and lifestyle factors.  Among these factors, obesity and parity are 
reviewed in the later parts of this section.  In general, luminal A and TNBC/BLBC have been 
intensively studied with clear differences observed.  Relatively little is known regarding the risk 
factors for Her2-positive tumors and luminal B tumors, which partially contributes to intra-
subtype heterogeneity, potential misclassification, and the rarity of the two subtypes.  
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Age at diagnosis has been widely studied in association with subtype.  Patients with 
TNBC/BLBC tend to be younger than patients with luminal A and Her2-positive tumors (66-72).  
This difference has been remarkably consistent across different-sized studies and in different 
multi-racial/ethnic populations (44, 46, 53, 66, 71, 73-75).  
Racial differences in subtype prevalence have also been found consistently.  African 
American and Hispanic women are more likely to have TNBC/BLBC compared to white women 
(46, 70-72, 76, 77).  Her2-positive tumors were more likely to affect Hispanic or Asian women 
(43, 46, 77).  The mechanism underpinning the association of race and subtype is not well 
understood and remains under investigation.  Race is a complex construct consisting of both 
environmental and genetic differences, each of which may contribute to differences in subtype-
specific risk.  However, some have argued that racial differences may be independent of 
socioeconomic status (SES) (43, 78). 
Aside from parity, other reproductive factors have been reported to be associated with 
subtypes.  Breastfeeding has been associated with lower risk across all subtypes (53, 67, 69, 71, 
76, 79, 80).  This protective effect was stronger in, or limited to, BLBC/TNBC in some studies 
(70, 76, 80), while other studies reported the largest decrease in risk among luminal A or luminal 
tumors (66, 71, 79).  In addition, younger age (<30 years) at first full-term birth was associated 
with TNBC (70), while older age (≥ 30 years) was associated with luminal tumors (66).  
Other breast cancer factors have been less studied and some of them showed heterogeneous 
associations with breast cancer subtypes.  Hormone replacement therapy (HRT) has been 
associated with luminal and Her2-positive tumors (66, 73, 77).  Women with family history of 
breast cancer tend to have higher risk for luminal tumors (66, 67) and for TNBC before 45 years 
(81, 82).  The association of early age at menarche with breast cancer subtype is controversial.  
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Some studies found it to be associated with luminal and Her2-positive tumors (67, 76, 83, 84), 
but other studies found it to be associated with TNBC (70, 71, 82).  Lower SES demonstrates a 
positive relation with TNBC and Her2-positive tumors (71, 72).  Current smoking also showed a 
positive association with Her2-positive tumors in one study (71).  This study also found that 
higher levels of physical activity were associated with decreased risk of all tumor types, except 
for luminal A (71).  
Inconsistent associations between breast cancer subtypes and these risk factors across 
studies could be explained by differences in study populations, adjusted confounders, or study 
sample size.  The measurement of exposures, such as lactation, smoking, and physical activities, 
is challenging and varies across studies, which may contribute to the observed inconsistency.  
Similarly, approaches in subtype categorization might impact the findings across studies.  For 
example, besides ER, PR, Her2, and CK5/6, some studies used Her1, Ki-67, or proliferation 
grade to define BLBC and luminal tumors (73, 85, 86).  This misclassification will be improved 
after the release of standard (56, 57) and after further progress in our understanding of intrinsic 
subtype (35, 36, 60).  Finally, inconsistent associations of rare subtypes with risk factors may 
result from small sample sizes. 
1.1.3. Distinct prognosis by intrinsic subtype 
Histologically similar tumors have variable prognoses and response to therapy, and these 
differences in clinical behavior are believed to be due to molecular differences (85).  Indeed, 
intrinsic subtypes have shown significant prognostic and predictive value in breast cancer 
outcomes.  
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Pattern of relapse and metastasis  
One measure of heterogeneous outcomes in breast cancer is the rate of relapse.  TNBC and 
Her2-positive tumors have higher incidence of locoregional recurrence than other subtypes.  A 
recent meta-analysis of 12,592 patients reported an approximately three-fold higher risk of 
locoregional recurrence among TNBC and Her2-positive tumors compared to luminal tumors 
after breast-conserving therapy (87).  Similar higher risk for TNBC and Her2-positive tumors 
was also observed in patients with mastectomy (87).  These results are consistent with studies of 
BLBC (88-90).  Early blood-borne dissemination has been hypothesized to occur more 
commonly in BLBC (91).  Compared to BLBC/TNBC, Her2-positive tumors more frequently 
exhibited lymphovascular invasion (41, 44-46, 73, 80) and have more frequent locoregional 
recurrence following breast-conserving therapy (87).  
Similarly, TNBC and Her2-positive tumors have higher risk for distant metastasis than 
luminal tumors (44, 92).  Of note, the location of metastasis also varies by intrinsic subtype.  In 
general, BLBC and Her2-positive tumors are more likely to develop brain and lung metastases, 
while luminal tumors are associated with bone metastases (46, 62, 93-98).  Some studies also 
suggest that Her2-positive tumors more frequently metastasize to liver (46, 62, 97).  These 
findings, in turn, support subtypes as distinct biological variants of breast cancer that predispose 
patients to different outcomes. 
Overall and breast cancer-specific survival  
Significant differences in prognosis exist among intrinsic subtypes, with BLBC and Her2-
positive tumors showing the shortest overall and disease -free survivals (26, 33, 88, 90, 99, 100).  
TNBC has the worst overall and disease-free survival of any subtype (43, 72, 83).  Five-year 
overall survival rate of TNBC has been found to range from 47.7%-85.5% (43-45, 72) and five-
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year disease-free survival was 76.0% (43).  BLBC has been found to be similar, with five-year 
overall survival/metastasis-free survival reported between 58% and 66% (26, 33, 88, 90, 99, 
100).  The estimated five-year overall/disease-free survival percentages of Her2-positive tumor 
ranged from 63.0%-83.2% and 77.5%-79.1% before and after Trastuzumab treatment, 
respectively (43-45).  In contrast, luminal tumors carry a better prognosis, with five-year overall 
survival and five-year metastasis-free survival up to 93.3% and 86% respectively (37, 45).  
Luminal B tumors demonstrate noticeably worse outcomes than luminal A tumors, which may be 
partially due to variation in response to treatment (26, 33, 99, 101).  
Effect modification of the association between intrinsic subtype and breast cancer 
prognosis by race/ethnicity has been evaluated (43, 72, 83).  In one analysis based on a subset of 
the women’s CARE (contraceptive and reproductive experiences) study, the black-white 
difference was only observed in all-cause mortality among old women (50-64 years) with 
luminal A tumors (HR=1.88, 95% CI=1.30-3.79), while no black-white differences in mortalities 
(all-cause and breast cancer-specific mortalities) were observed for women with TNBC (83).  
Therapy response  
Different biological characteristics also result in different therapy responses.  Luminal 
tumors have more treatment options than other subtypes, including endocrine therapy.  
Therefore, they usually have better prognosis.  The prognosis of Her2-positive tumors is 
expected to be improved with the use of anti- ERBB2 monoclonal antibody agents, which is 
generally supported by recent data (102).  Since TNBC/BLBC tumors do not express the target 
for hormone therapy and anti-ERBB2 therapies, cytotoxic chemotherapy (such as DNA-
damaging agents) is the only available systemic treatment.  Although novel treatments are under 
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study (103, 104), fewer treatment options available for BLBC are considered the main reason for 
the poor prognosis (105).  
1.2. Obesity, breast cancer risk and prognosis 
1.2.1. Obesity, intrinsic subtype, and breast cancer risk 
The association between obesity and breast cancer risk has been intensively studied.  In a 
recently published meta-analysis of 2,175,419 subjects, obesity showed a protective effect in 
premenopausal women (OR=0.93, 95% CI=0.86-1.02) and a detrimental effect in 
postmenopausal women (OR=1.15, 95% CI=1.07-1.24) (106).   For premenopausal women, the 
proposed explanation for these associations was that obesity is associated with a greater number 
of anovulatory cycles and thus lower levels of estradiol.   For postmenopausal women, it was 
proposed that obesity is associated with aromatization of steroid precursors to estrogens and 
therefore higher levels of estradiol (107).  Other complimentary mechanisms may also apply, 
such as insulin-insulin-like growth factor axis, and systemic/chronic inflammation (108).  
Considering tumor subtype provides novel insights into the association between obesity 
and breast cancer risk.  Based on a meta-analysis of studies of breast cancer subtype defined by 
ER and PR, the menopause-modified effect of obesity was stronger when the analysis was 
limited to ER+/PR+ tumors (premenopausal: RE (risk estimate)=0.80, 95% CI=0.70-0.92. 
Postmenopausal: RE=1.82, 95% CI=1.55-2.14), while no associations were observed for ER-
/PR- (premenopausal: RE =1.04, 95% CI=0.92-1.17. Postmenopausal: RE =1.09, 95% CI=0.96-
1.23) (13).  The magnitudes of the associations among hormone-positive tumors were similar to 
the results in women with luminal tumors.  Turkoz and colleagues found that being overweight 
or obese significantly decreased the risk of luminal tumors (overweight: OR=0.63, 95% CI=0.43-
0.95. Obesity: OR=0.50, 95% CI=0.32-0.76) among premenopausal women (66).   
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Regarding intrinsic subtype, most of the studies observed a positive association between 
obesity and TNBC/BLBC, with a possible difference by menopause status.  Kwan and 
colleagues found that, compared to luminal A tumor patients, premenopausal women with TNBC 
were more likely to be overweight (OR=1.82, 95% CI=1.03-3.24) or obese (OR =1.97, 95% 
CI=1.03-3.77) (77).  Similar associations among premenopausal women were also detected in a 
large population (n=6175) from the National Comprehensive Cancer Network (46).  These 
findings based on case-only studies are also confirmed in a case-control study, where compared 
to healthy premenopausal controls, premenopausal women with higher weight level (categorized 
as underweight, normal weight, overweight, or obese) had higher risk for TNBC (OR=1.67, 95% 
CI=1.22-2.28) (81).  These results from U.S. studies are consistent with studies from other 
countries.  Yang and colleagues found that BMI was associated with higher risk for BLBC (per 
five BMI units, OR=1.18, p=0.003) among premenopausal Polish women (73).  A study in 
Turkey found that overweight or obesity significantly increased the risk of TNBC (overweight: 
OR=1.89, 95% CI=1.06-3.37. Obesity: OR=1.90, 95% CI=1.00-3.61) among premenopausal 
women (66).  Similar findings were also observed in premenopausal Chinese women, who 
experienced a nearly four-fold increased risk of TNBC among obese patients compared to under-
weighted patients (OR=3.7, 95% CI=1.2-12.1) (109).  In contrast to the observations in 
premenopausal women, the subtype-specific effects of obesity disappeared after menopause, and 
obesity shows a homogeneously positive association with breast cancer (46, 66, 73, 76, 77, 81, 
109).  The association between obesity and luminal B or Her2-positive breast cancer has been 
less reported.  Gaudet et al. found an increased risk for luminal B tumors among obese patients 
(81).  Weight gain since 18 years and BMI at age 18 was also reported to be associated with 
higher risk for luminal B and Her2-positive tumors (80). 
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Besides menopause status, race/ethnicity has been evaluated as a potential effect modifier 
in some studies.  According to the most recently published meta-analysis among premenopausal 
women, a weak inverse association with BMI was observed for both African American and 
white women (AA: RR per 5kg/m2=0.95, 95% CI=0.91-0.98. White: RR=0.93, 95% CI=0.91-
0.95), while a positive association was observed in Asian women (RR=1.08, 95% CI=1.01-1.16) 
(110).  Interestingly, WHR showed different results from BMI, with WHR associated with 
increased risk for breast cancer across all racial groups (African American: RR for 0.1 unit 
increment=1.06, 95% CI=1.01-1.12. White: RR=1.09, 95% CI=1.04-1.14. Asian: RR=1.19, 95% 
CI=1.15-1.24) (110).  These differences may reflect the different prevalence of subtypes by 
racial/ethnic groups.  However, so far few studies assessed the association by both race and 
subtype.  
Compared to BMI, few studies have used other types of anthropometric indices to 
evaluate obesity.  Different indices capture different aspects of obesity.  For instance, BMI is 
considered to better reflect overall body obesity, while WHR measures central/abdominal 
obesity.  It has been suggested that the association of obesity with breast cancer risk varies 
depending on the specific measurements used (110).  However, little is known regarding the 
difference between measures of obesity by intrinsic subtype.  In CBCS, Millikan and colleagues 
detected an association with WHR, but not BMI (76).  However, the association with WHR was 
not confirmed in other study (71).  
1.2.2.  Obesity, intrinsic subtype, and breast cancer prognosis 
The prognostic effect of obesity has been investigated extensively.  Past reviews and meta-
analyses have consistently found an association between obesity and poor breast cancer survival 
(111-116).  Based on a recent meta-analysis of 43 studies, compared with non-obese breast 
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cancer patients, obese breast cancer patients had a 33% increased risk for poor outcomes (HR for 
all cause death= 1.33, 95% CI=1.21-1.47; HR for breast cancer-specific death=1.33, 95% 
CI=1.19-1.50) (113).  In addition, obesity is associated with increased risk of contralateral breast 
(RR=1.37, 95% CI=1.20-1.57) and a second primary breast cancer (RR=1.40, 95% CI=1.24-
1.58) (116).  The relationship between obesity and prognosis varies by menopausal status, with a 
stronger effect observed in pre-menopausal than post-menopausal women (113, 117).  Although 
the understanding of obesity’s role in prognosis is mostly based on studies where BMI was 
measured at or after diagnosis of breast cancer, a meta-analysis suggested that obesity before 
breast cancer diagnosis had a stronger association with prognosis (114).  Two studies examining 
the impact of WHR on breast cancer mortality suggested that high WHR had an unfavorable 
effect on breast cancer prognosis (118, 119), although WHR’s association with mortality was 
weaker than that of BMI (113). 
Variation has been observed in the association between obesity and prognosis by breast 
cancer subtype.  In a meta-analysis of 14 studies, overall mortality in obese women was worse 
compared with non-obese women (pooled HR=1.31, 95% CI=1.17–1.46) for ER+/PR+ tumors, 
as well as for ER-/PR- tumors (HR=1.18, 95% CI=1.06–1.31).  The pooled HRs for breast 
cancer-specific mortality were 1.36 (95% CI=1.20–1.54) for ER+/PR+ tumors and 1.46 (95% 
CI=0.98–2.19) for ER-/PR- tumors, respectively (120).   
Studies addressing whether the effect of obesity on breast cancer outcomes varies by 
intrinsic subtype are few, and the results are mixed (Table 1.1). One study in premenopausal 
women reported an increased risk for breast cancer-specific mortality associated with obesity 
(obese vs normal weight: HR=1.4, 95%CI=1.0-2.1) among TNBC, but no association was 
observed among luminal tumors (66).  This finding is inconsistent with other studies, where no 
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association was observed between obesity and prognosis among TNBC (121-124).  Sparano and 
colleagues used data of three trials (N=4770 breast cancer patients overall) and found that, 
among TNBC patients, obesity was not associated with overall mortality (obese vs normal 
weight: HR=1.11, 95% CI=0.85-1.46), disease-free mortality (HR=1.02, 95% CI=0.80-1.30), or 
breast cancer-specific mortality (HR=1.00, 95% CI=0.74-1.36) (121).  However, among luminal 
A tumors, obesity was positively associated with all of the three prognostic measures (HR for 
overall death=1.37, 95% CI=1.13-1.67; HR for disease-free death=1.24, 95%CI=1.06-1.46; HR 
for breast cancer-specific death=1.40, 95% CI=1.11-1.76) (121).  The investigators found similar 
results when subtype was defined by ER/PR status (121).  These findings are consistent with a 
recently published hospital-based study in Japan, where among ER+/PR+ patients, but not ER-
/PR- patients, women with higher BMI tended to have poorer overall and breast cancer-specific 
survivals compared with women with lower BMI (117).  The null association was also observed 
in similar TNBC-only studies (122-124).  While low statistical power due to small sample size 
may contribute to the null association, the magnitude of association was notably close to the null 
value of 1 in these studies on TNBC (121-123).  Few studies have evaluated obesity in 
association with survival following Her2-positive tumor diagnosis.  One large study based on 
data from an adjuvant treatment trial did not detect any prognostic value of obesity among Her2-
positive tumors (121).  Other studies found that obesity was associated with higher risk for 
mortality and distant metastasis in this subtype (66, 121, 125).  
Whether menopausal status modifies the association between obesity and breast cancer 
prognosis is not clear.  A meta-analysis reported increased hazard for overall mortality in obese 
versus non-obese women (HR=1.23, 95% CI=1.07–1.42) among premenopausal patients and 
also among postmenopausal women (HR=1.15, 95% CI=1.06–1.26).   For breast cancer-specific 
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mortality, increased risk for obese versus non-obese women was also found for premenopausal 
women (HR=1.18, 95% CI=0.82–1.70) and postmenopausal women (HR=1.38, 95% CI=1.11–
1.71), respectively (120).  The relationships between obesity, prognosis, breast cancer subtype, 
and menopausal status have been less studied, partially due to sparse sample size when 
stratifying on multiple variables.  While some studies did not detect different prognoses by 
menopausal status (122, 126), Dignam and colleagues limited analysis to ER- breast cancer and 
found a positive association between obesity and the risk for contralateral breast cancer among 
postmenopausal patients, but not among premenopausal patients (127).  Another study in 
premenopausal patients detected an association with breast cancer-specific death among TNBC 
and Her2-positive tumors (both ER-negative subtypes), but not among luminal tumors (66).   
While race/ethnicity appears to modify subtype-specific survival (41, 83, 100, 128) and 
obesity-associated survival (129-132), so far no data have been published evaluating obesity, 
race/ethnicity, subtype, and breast cancer outcome simultaneously.   
1.3. Parity, breast cancer risk, and prognosis 
1.3.1. Parity, intrinsic subtype, and breast cancer risk 
The association between parity and breast cancer risk has been extensively studied. Parity, 
narrowly defined as the number of live births a woman has given, has been linked to breast 
cancer as a protective factor for a long time (133, 134).  Later studies show that for each 
individual birth, the effect of parity on breast cancer risk varies temporally (usually defined as 
year since birth), with a transiently increased risk in the first 5-7 years after last child birth (135, 
136).  This transient increase in risk is believed to be caused by stimulation of the malignant cell 
transformation during breast involution (137-139), but several years after birth there is a long-
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term reduction in risk.  Reduced lifetime risk in later years after childbirth is believed to be 
induced by the differentiation of normal mammary stem cells (135, 140).  
The heterogeneity of breast cancer is reflected in different relationships between parity and 
various subtypes.  In a recent meta-analysis on the association of parity (measured by number of 
births) and breast cancer by ER/PR status, parity reduced the risk for ER+/PR+ tumors (relative 
risk (RR) per birth=0.89, 95% CI=0.84-0.94), but not for ER-/PR- tumors (RR per birth=0.99, 
95% CI=0.94-1.05) (11).  These results are consistent with the findings of studies on intrinsic 
subtype.  Compared to luminal tumors, high parity and recency of last birth/pregnancy are 
associated with an increased risk for BLBC/TNBC (69-71, 73, 76, 81, 141).  In addition, a 
positive association between parity and risk of Her2-positive tumors was also observed (76, 85).    
Racial/ethnic groups have different distributions of reproductive factors and tumor 
subtypes, respectively.  Results to date suggest quantitative differences by race/ethnicity (142-
144), with a stronger protective effect of parity on overall breast cancer risk observed in African 
American women than white women (144).  However, little is known as to whether 
race/ethnicity adds another layer modifying the relationship between parity and breast cancer 
subtype.  
1.3.2. Parity, intrinsic subtype, and breast cancer prognosis 
While epidemiological research has established associations between parity and breast 
cancer risk, it remains unsettled whether parity has prognostic value in breast cancer.  While 
some studies reported no association between parity and prognosis (88, 145-156), some studies 
reported that parity, particularly high parity (n≥4), was an adverse prognostic factor (155, 157-
164), and still others showed a better prognosis among parous women (149, 165, 166).  
Temporal factors such as time since last birth are thought to play a particularly critical role in 
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breast cancer prognosis.  Based on a recent meta-analysis of 30 studies, breast cancer diagnosed 
within 2 years after birth/pregnancy (usually defined as pregnancy-associated breast cancer) had 
a higher risk for death (HR=1.44, 95% CI=1.27-1.63) and relapse (HR=1.60, 95% CI=1.19-2.16) 
(167).  The effects of parity on prognosis are likely to be attenuated with time since 
pregnancy/birth (150, 153, 162, 163, 168-171).  
The association between parity and survival seems to vary with the age of the patients.  In 
young patients (definition varies across studies, at most younger than 50 years), nulliparous 
women appeared to have a better prognosis than parous women (157, 161-163), while an inverse 
relationship was observed in older patients (>50 years) (157, 172).  Meanwhile, some studies 
have found that the prognostic effect of recent birth was limited to young women, but not older 
women (152, 154, 157, 162, 163, 171, 173).  
ER/PR status has been considered in the studies on the association of parity and breast 
cancer survival, but usually as a confounder rather than an effect modifier (145, 151, 162, 163, 
174-176).  So far there are only two studies examining parity associations with survival by breast 
cancer subtype (160, 171).  In the study by Trivers and colleagues among women aged 20-54, 
the associations of parity and years since last birth with all-cause mortality did not depend upon 
ER status (effect estimates were not reported) (160).  The effect modification of intrinsic subtype 
was also examined among young Japanese women (age range=20-44), and the adverse effect of 
recent birth on all-cause mortality was only observed in women with luminal A tumors (0-2 
years vs nulliparous, HR=3.07, 95%CI=1.30-7.27) (171).  Little is known regarding the role 
race/ethnicity or menopausal status plays in the association of parity, breast cancer subtype, and 
prognosis.  
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1.4. Linkage between risk factors and prognosis 
Whether the influence of risk factors on breast cancer etiology is persistent after disease 
diagnosis is critical to understanding mechanisms and to improve prognosis.  The rationale 
underlying the linkage between risk factors and prognosis in previous studies was based on 
biological mechanisms, which are similar to those relating risk factors to cancer incidence.  Few 
previous studies characterize these relationships considering the potentially differences in disease 
development and progression, or assess the differences in breast cancer outcomes by risk factors 
and by prognosis measures (BC-specific mortality vs overall mortality).  In this project, we 
evaluated the association of obesity and parity with breast cancer prognosis, with an emphasis to 
address these issues. 
Obesity status is dynamically changing and, over the lifespan, cumulative.  Most of the 
evidence of its relationship with breast cancer risk comes from studies in which obesity status 
was measured close to breast cancer diagnosis.  Using this data to evaluate the obesity/breast 
cancer association assumes that obesity status measured around diagnosis (obesityt1) is highly 
correlated with obesity status during the phase of causal action (obesityt0) (Figure 1.1 A).  This 
assumption is reasonable given the previous literature (177, 178).  The same assumption is 
employed in studies of the association between obesity and prognosis.  In the discussion below, 
obesity is conceived as the status at t0 that is measured at t1.  As shown in Figure 1.1 A, obesity 
could influence breast cancer prognosis by altering susceptibility to more aggressive subtypes, or 
through a pathway other than breast cancer subtype (e.g. through treatment tolerance).  Based on 
this model, after accounting for obesity’s influence on subtype susceptibility in analysis stratified 
by intrinsic subtype, there will be a “residual” association of obesity with breast cancer-specific 
mortality observed within each stratum due to its direct effect on breast cancer prognosis.  The 
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magnitude of the “residual” association will vary by subtype.  For example, since BLBC is the 
most aggressive subtype with the fewest treatment options, the subtype itself is likely to explain 
the majority of poor prognosis. Therefore, we would expect that obesity is not associated with 
breast cancer-specific mortality, which has been indicated in several recently published studies 
(121-124).  These differences in the association among intrinsic subtypes will provide 
information on the different role of obesity in development and progression of each subtype.  
Since obesity has been shown to impact numerous diseases, particularly chronic diseases, its 
association with overall mortality is likely to be greater than BC-specific mortality, particularly 
in long-term survival (83, 179).   
Different risk factors influence breast cancer prognosis by different pathways.  In previous 
studies, the association of number of births/pregnancies with overall mortality/breast cancer-
specific mortality disappeared after adjusting for tumor characteristics (147, 151, 157).  
Therefore, we hypothesize that its association with breast cancer prognosis is only through breast 
cancer, without a direct pathway (Figure 1.1 B).  We will not observe its effect in the analysis 
stratified by intrinsic subtype, if subtype counts for tumor differences mediating the prognostics 
effect of parity.  Other data suggested that breast cancer-specific mortality yielded similar 
estimates as all-cause mortality (155, 166), and even stronger estimates in some analyses (158, 
160, 166).  These data support our hypothesis that parity’s effect on breast cancer prognosis is 
mainly due to its influence on breast cancer, but not deaths due to other diseases.  
Unlike the number of births/pregnancies, the association of birth recency with breast cancer 
outcome remained after adjusting for tumor characteristics and treatment (167).  This association 
with survival suggests that these traditional parameters of tumor characteristics may not 
appropriately capture the unique properties of pregnancy-related breast cancer.  Recent studies 
20 
 
showed TNBC was overrepresented among pregnancy-related breast cancer (141, 176, 180), 
which suggests intrinsic subtype may work as a more accurate phenotype to describe its 
underlying properties.  In turn, considering intrinsic subtype in the analysis on birth recency and 
breast cancer prognosis may illuminate the etiology of pregnancy-related breast cancer and better 
characterize the prognostic effect of parity.   
1.5. Limitations 
1.5.1. Potential selection bias 
Our study examined the association of obesity and parity with breast cancer prognosis by 
intrinsic subtype among breast cancer patients.  Since obesity and parity are risk factors for 
breast cancer, evaluating their prognostic effect among breast cancer patients may induce 
selection bias, specifically collider stratification bias, due to conditioning on breast cancer, which 
is a collider in this context (Figure 1.2) (181).  In the study limited to breast cancer patients, 
unmeasured/unknown confounders (U) of breast cancer and breast cancer prognosis may work as 
a bypass linking obesity/parity to mortality, resulting in a spurious/distorted association between 
obesity/parity and mortality (182-186).  The magnitude of this bias depends on several factors: 
(a) the presence of unmeasured/unadjusted factors (U); (b) the prevalence of U in the study 
population; (c) the effect of U on breast cancer risk in exposed individuals; (d) the effect of U on 
breast cancer risk in unexposed individuals; and (e) the effect of U on prognosis among breast 
cancer patients (183, 187).  
Since breast cancer-specific mortality is already conditional on breast cancer, collider 
stratification bias does not apply to the analysis of breast cancer-specific mortality.  Here we 
mainly discuss the influence of this bias on overall survival.  Based on the analysis by Glymour 
and colleagues, selection bias will distort the association only if “U” has a large effect on breast 
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cancer risk or mortality (in their simulation: RR>2.5) (183).  Although a large proportion of 
breast cancer incidence and mortality cannot be explained by known factors, it is unlikely that 
unidentified variables with large effects on risk and progression, or highly-prevalent unidentified 
variables with small effects, exist because breast cancer is such an intensively-studied disease.  
Most likely, the effects of unknown factors are minor, functioning as white noise without biasing 
results considerably.  Additionally, since the CBCS has minimized unmeasured factors by 
collecting information on almost all identified predictors of breast cancer incidence and survival, 
the magnitude of this bias is less likely to be large enough to change our results qualitatively.  
Moreover, Figure 1.2 shows that the “U” has to be a risk factor for breast cancer and also 
influences overall survival through diseases other than breast cancer.  Therefore, this factor 
would have to be a common cause of two diseases, one of which is breast cancer.  Concurrence 
with a second lethal disease is not common for young women with breast cancer, but may exist 
for older patients.  In addition, long follow-up may provide enough time to develop a second 
lethal disease with common causes.  Therefore, in our proposed project, the results of older 
women and long-term survival are more likely to be influenced by collider stratification bias, 
although the bias likely will not be large. 
1.5.2. Exposure misclassification 
In the proposed study, we assume that obesity and parity status do not change after the 
diagnosis of breast cancer.  This assumption may not hold since many studies have observed 
weight change due to treatment, age, and lifestyle factors (188, 189).  It was estimated that 50-
96% of breast cancer patients experienced weight gain (188).  Since we only have information on 
BMI around the time of diagnosis, our results may be biased by weight changes during follow-
up.  An analysis of 12,915 breast cancer patients from four prospective cohorts found that the 
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mean weight change was 1.6 kg during a follow-up averaging 8.1 years (189).  This weight 
change is not likely to cause a considerable proportion of patients to change their obesity 
category.  Moreover, we adjusted for key factors associated with weight gain in our analysis, 
such as age, menopausal status, tumor stage, and SES, to minimize this information bias. 
Compared to obesity, parity is less likely to change after breast cancer diagnosis.  
Hartmen and colleagues reported that the birth rate among young breast cancer survivors (≤45 
years) was about half of the general population (standardized birth ratio=0.52, 95% CI=0.47-
0.57) (190). Therefore, the static assumption is reasonable for parity. 
1.5.3. Subtype misclassification 
Although intrinsic subtype has largely improved the categorization of breast cancer 
heterogeneity, the subtypes defined by the IHC approach in CBCS are similar, but not identical, 
to intrinsic subtypes by cDNA microarray.  Therefore, misclassification of subtype is 
unavoidable, particularly for luminal A and B tumors.  In CBCS, the definition by Nielsen and 
colleagues (55) for luminal B did not identify all luminal B tumors as only 30-50% of this 
subtype expressed Her2 receptor, which leads to some luminal B tumors being classified as 
luminal A.  This misclassification may result in the observed prognosis of luminal A tumors 
being worse than it should be (41).  The IHC-based definition of luminal B has been updated 
recently as tumors that are (a) ER-positive and Her2-negative and (Ki-67 ≥ 14% or PR ≤ 20%), 
or (b) ER-positive and PR-positive and Her2-positive (35, 57).  In the proposed project, to avoid 
the bias due to this misclassification, we combined luminal A and B tumors as a single luminal 
subtype.   
In 2010 the American Society of Clinical Oncology (ASCO) lowered the IHC cutoff for 
determining ER positivity from the previous value of 10% to 1% (191).  The information of ER 
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positivity in the CBCS Phases I and II was from clinical records, where cutoffs ranged from 
more than 0% to more than 20%.  Therefore our intrinsic subtyping may classify some luminal 
tumors, defined by the updated cutoffs, as Her2-positive or basal-like tumors.  This 
misclassification will dilute the differences among subtype, and consequently may cover the 
modification of subtype on the associations of obesity and parity with breast cancer prognosis.   
1.5.4. Others 
CBCS Phases I and II do not have treatment information.  Treatment of breast cancer is 
determined by both physician recommendation and patient preferences.  Physician 
recommendation is mainly based on comprehensive consideration of disease-related factors (e.g. 
tumor stage and hormone receptor status) and patient-related factors (e.g. age, co-morbidities) 
(192, 193).  Patient preference is mainly influenced by education, culture, and income (194, 
195).  CBCS includes information on most of these determinants.  In the proposed project, 
adjusting for tumor and patient characteristics could minimize this potential bias.  The 
development of trastuzamab and other Her2-targeted agents in recent years has improved 
prognosis of Her2-positive tumors (102).  The CBCS was conducted prior to the introduction of 
trastuzumab and other Her2-targeted agents, which decreases the bias due to temporal changes in 
therapy. 
In this study, we considered race and menopausal status as potential effect modifiers.  Too 
many stratification variables may result in sparse cell counts and low statistical power to detect 
associations.  In CBCS, the sample size of Her2-positive tumor is small (n=116, 8% of CBCS 
subjects).  Therefore, we may have low power to get precise estimation for this subtype.   
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1.6. Summary 
Breast cancer is a heterogeneous disease with multiple intrinsic subtypes having different 
risk factors and prognoses.   Obesity and parity, two factors that have consistently different 
associations with different intrinsic subtypes, have been linked to breast cancer prognosis in 
previous studies.  However, little is known whether these relationships are modified by intrinsic 
subtype.  This proposed project is the first to investigate the associations of parity and obesity 
with breast cancer prognosis by intrinsic subtype.  Our results will contribute to characterization 
of different pathways linking risk factors to prognosis, and provide important insights to 
optimize treatment and management strategies in breast cancer patients and ultimately improve 
breast cancer survival.
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Table 1.1: Obesity and breast cancer survival by intrinsic subtype 
Author 
(year) 
Study design Population Obesity Subtype Results 
Mazzarella 
(2013) a 
  
Hospital-based 
study in Italy 
  
1250 non-metastatic Her2+ BC 
before Trastuzumab use. 43% 
35-50 years; 41% 51-65 years. 
Median FU=8.2 years. 
BMI at 
diagnosis 
 Obese vs under/normal 
 Her2+/ER+ Recurrence risk: HR=0.75, 95% 
CI=0.43-1.31 
  Overall mortality: HR=1.05, 95% 
CI=0.53-2.09 
 Her2+/ER- Overall mortality: HR=1.79, 95% 
CI=1.03-3.10 
  Recurrence risk: HR=1.34, 95% 
CI=0.84-2.13 
Turkoz 
(2013) b 
Hospital-based 
study in 
Turkey 
733 non-metastatic 
premenopausal BC. Mean 
age=40.13 years. Median 
FU=2.4 years 
BMI at 
diagnosis 
 Obese vs normal 
 TNBC BCSM: HR=1.4, 95%CI=1.0-2.1, 
p=0.04 
 Her2+ BCSM: p=0.037. HR and 95% CI 
not provided 
 Luminal BCSM: p=0.40. HR and 95% CI 
not provided 
Mowad 
(2013) c 
Medical 
center-based 
study in US 
183 stage 1-3 TNBC. Mean 
age=49.8 years. Median 
FU=3.54 years. 69% AA 
BMI at 
diagnosis 
 Not clearly described the reference 
level. Likely obesity level used as 
ordinal variable 
 TNBC Overall mortality: HR=1.36, 95% 
CI=0.77-2.42 
  Recurrence risk: HR=1.01, 95% 
CI=0.67-1.52 
Dawood S 
(2012) d 
Hospital-based 
study in US 
2311 stage 1-3 TNBC. ~50% 
<50 years. Median FU=3.25y. 
~20% AA. 
BMI at 
diagnosis 
 Obese vs over-weighted:  
 TNBC Overall mortality: 1.00, 95% 
CI=0.83-1.20 
  Recurrence risk: 1.09, 95% 
CI=0.92-1.29 
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Table 1.1: Obesity and breast cancer survival by intrinsic subtype 
Author 
(year) 
Study design Population Obesity Subtype Results 
Sparano JA 
(2012) e 
Data from 
adjuvant 
treatment trials 
in US 
4770 stage 1-3 BC. Age ranged 
22-84. Median FU= 7.9 years. 
~85% white. 
BMI at 
diagnosis 
 Obese vs normal 
 Luminal Overall mortality: HR=1.37, 95% 
CI=1.13-1.67 
  Recurrence risk: HR=1.24, 95% 
CI=1.06-1.46 
 Her2+ Overall mortality: HR=0.99, 95% 
CI=0.73-1.34 
  Recurrence risk: HR=1.06, 95% 
CI=0.82-1.38 
 TNBC Overall mortality: HR=1.11, 95% 
CI=0.85-1.46 
  Recurrence risk: HR=1.02, 95% 
CI=0.80-1.30 
Ademuyiwa 
FO (2011) f 
Hospital-based 
study in US 
418 stage 1-3 TNBC. Mean 
age=55 years. Median FU=3.1 
year. 80% white. 
BMI at 
diagnosis 
 Obese vs normal:  
 TNBC only Overall mortality: HR= 0.94, 95% 
CI=0.54-1.64  
  Recurrence: HR= 0.81, 95% 
CI=0.49-1.34 
a Adjusted for age at diagnosis, menopausal status, number of positive lymph nodes, tumor size, grade, percent of estrogen receptor-positive 
cells (as a continuous variable), perivascular invasion and type of surgery. 
b Adjusted for age, tumor size, nodal involvement, grade, lymphvascular and perineural invasion, extracapsular extension and hormonal status. 
c Not explicitly described in the text. Likely the HRs were adjusted for age, race, tumor grade, T stage, N stage and PMRT (postmastectomy 
radiotherapy). 
d Adjusted for age, race, stage of disease, lymphovascular invasion, systemic adjuvant treatment, and radiation therapy. 
e The HRs were adjusted for age, race, premenopausal vs other, tumor size, axillary nodal status, surgery, use of radiation therapy, and use of 
systemic therapy.  
f Adjusted for age at diagnosis, race, receipt of chemotherapy, year of diagnosis, grade, histology, stage, and presence of lymphovascular 
invasion
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Figure 1.1: Hypothesized associations between obesity, parity, intrinsic subtype, and breast 
cancer prognosis 
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Figure 1.2: Collider stratification bias 
 
 29 
 
CHAPTER 2: SPECIFIC AIMS 
During the past ten years, the understanding of heterogeneity of breast cancer has been 
improved by global gene expression analyses.  Several intrinsic subtypes have been identified, 
including luminal A, luminal B, Her2-enriched, and basal-like (25, 26, 196).  These breast cancer 
subtypes show significant differences in risk factor profiles (41, 73, 76, 77, 141), as well as 
prognosis (41, 88, 97, 100, 197, 198).  The recognition and improved classification of intrinsic 
subtype have been adding new insights to breast cancer research. 
Whether breast cancer risk factors influence prognosis has great public health 
significance.  However, findings have been mixed (88, 114, 115, 157, 158).  Moreover, few 
studies have considered the role of breast cancer heterogeneity in the analysis.  In this project, we 
studied obesity and parity, two risk factors that have consistently shown distinct association with 
breast cancer subtype and also have been suggested to affect breast cancer outcomes.   
Aim1: To evaluate whether obesity is associated with overall mortality and breast 
cancer-specific mortality, considering intrinsic subtype as an effect modifier.  We 
hypothesized that obesity was associated with higher overall and breast cancer-specific mortality 
among all breast cancers, but the magnitude of the association varied by subtype.  Obesity was 
evaluated by body mass index (BMI, based on anthropometric information self-reported prior to 
diagnosis and measured after the diagnosis during interview), and waist-to-hip ratio (WHR, 
based on anthropometric information measured after the diagnosis during interview).   
Aim2: To evaluate whether parity is associated with overall mortality and breast-
cancer specific survival, considering intrinsic subtype as an effect modifier.  We 
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hypothesized that parity was associated with higher overall and breast cancer-specific mortality 
among all breast cancers, but the magnitude of this association varied by subtype.  Parity was 
described by number of full-term births and time since last birth.  
The two parallel aims were addressed using the cases from the Carolina Breast Cancer 
Study (CBCS) (Phases I and II).  Vital status of included cases was ascertained through the 
National Death Index.  Cox regression methods was used to estimate adjusted hazard ratios (HR) 
and 95% confidence interval (CI) in all cases and stratified by breast cancer subtype.  Potential 
effect modification by race and menopausal status was also evaluated.  
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CHAPTER 3: RESEARCH METHODS 
3.1. Population and participants 
3.1.1. Carolina breast cancer study 
The CBCS is a population-based case-control study aimed at identification of genetic and 
environmental causes of breast cancer among African American and white women from North 
Carolina (41, 76, 199, 200).  The CBCS study area included 24 counties (including suburban, 
small town, and rural areas) in eastern and central parts of the state, with over-sampling of 
younger and African American women.  In this project, we included CBCS patients with 
invasive breast cancer who were recruited in the first two phases, Phase I (1993-1996) and Phase 
II (1996-2001).  
Breast cancer patients were identified from the North Carolina Central Cancer Registry 
using rapid case ascertainment.  Eligible patients were those who were newly diagnosed for a 
first primary breast cancer between May 1, 1993 and December 31, 2001, were aged 20-74 years 
at the time of diagnosis, and resided in the 24 counties.  Among eligible patients, cases were 
selected using randomized recruitment with predetermined probabilities, with the aim to balance 
representation by age (<50 y vs. ≥ 50 y) and race (African Americans vs. whites) to further 
improve the statistical validity of comparisons among these subgroups.  Under this strategy, the 
following sampling fractions were used: 100% of younger (defined as 20-49 years) African 
American women, 75% of older (defined as 50-74 years) African American women, 67% of 
younger white women, and 20% of older white women (200).  Other than the oversampling of 
younger and African American women by design, the CBCS population is approximately 
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representative of cases reported to the North Carolina Central Cancer Registry in the study 
region during the study period (200).   
For recruitment prior to patient contact, a letter was sent to the physician providing 
cancer care requesting permission to invite the woman to participate in the study.  Potential 
participants with physician permission were contacted first by letter and then by a telephone call.  
If a woman agreed to participate, an appointment was scheduled for an in-person interview at the 
woman’s home or other agreed-upon location.  Home visits and interviews for cases and controls 
were conducted by registered nurses and interviews lasted about 1-1.5 hours.  The interviewers 
were matched with patients on race for those aged 50 years or older.  Interviewers administered a 
structured questionnaire that included detailed information about family history of cancer and 
reproductive history, including age at menarche, age at first full-term pregnancy, number of 
children, breastfeeding, age at menopause, oral contraceptive use, and use of hormone 
replacement therapy.  Body measurements including waist and hip circumferences and weight 
were obtained at the time of the interview.  For cases, consent for retrieving tumor tissue, 
pathology reports, and medical documentation was obtained at the time of interview.   
The CBCS Phases I &II included 1,803 invasive breast cancer cases (787 African 
American and 1,016 white women).  The overall contact rate (contacted/eligible) and the 
cooperation rates (enrolled/contacted) of invasive cases were 97.6% and 78.0% respectively.  
The overall response rate (product of contact and cooperation rates) was 76.0%, with subgroups 
of patients ranging from 69.9% for African Americans aged 50 years or older to 81.2% for 
whites less than 50 years old (201, 202).  Compared with women who participated in the CBCS, 
nonparticipants were more likely to be of lower socioeconomic status, to have a lower 
educational level, and to have a recent history of unemployment (202). 
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All tumor blocks were processed at the University of North Carolina (UNC) SPORE 
Core Tissue Procurement Analysis Facility in Chapel Hill, NC.  Approval for release of 
formalin-fixed, paraffin-embedded tumor tissue blocks was obtained for 94% of cases.  Patients 
with smaller or early-stage tumors were less likely to provide blocks because they were either 
unavailable or had insufficient tissue for subtype analysis.  The Hematoxylin and Eosin (H&E)-
stained slides were produced from each of the paraffin-embedded blocks and reviewed in a 
standardized fashion by the study pathologist who was blinded to the demographic 
characteristics of participants.  The pathologist confirmed the diagnosis of breast cancer, 
assigned a histologic classification, and described tumor features in more detail (200).  All 
tumors were graded according to the Nottingham modification of the Scarff–Bloom–Richardson 
system (203), taking into account tubule formation (architectural grade), pleomorphism (nuclear 
grade), and mitotic activity (mitotic grade).  In 6 % of the cases, the grades could not be properly 
determined, usually due to an insufficient amount of diagnostic tissue or poor histology.   
The current project was limited to 1,140 invasive breast cancer patients with available 
information on intrinsic subtype.  In obesity analysis, the sample size was 1,109 after 
additionally excluding patients without information on BMI or WHR.   
3.1.2. Data acquisition 
Permission to use the data was obtained from the former principal investigator of CBCS, 
Dr. Robert Millikan and current principal investigator Dr. Andrew Olshan has subsequently 
confirmed permission to use the data.  Additionally, IRB approval was obtained for analyzing the 
data. 
3.2. Data analysis 
3.2.1. Exposure assessment and categorization 
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Obesity 
Obesity was measured by BMI and WHR to reflect different types of obesity. The 
information on height and body weight was self-reported prior to diagnosis and measured after 
the diagnosis during interview.   BMI was computed by dividing the weight in kilograms by the 
square of the height in meters.  The World Health Organization definition is used to classify 
patients as underweight (BMI <18.5 kg/m2), normal (BMI 18.5-24.9 kg/m2), overweight (BMI 
25-29.9 kg/m2), and obese (BMI ≥30 kg/m2).  In our analysis, the “underweight’’ and ‘‘normal” 
BMI classes was combined as one group.  Waist and hip circumferences were only measured at 
the time of interview.  WHR was calculated as the ratio of waist to hip circumference (cm) and 
used as a measure of abdominal adiposity.  Cut points for WHR were tertiles (two cutoff points: 
0.77 and 0.83) based upon the distribution in controls (76). The lowest obesity level was used as 
the reference in the analysis. 
Parity 
Parity was evaluated as both number of full-term live births and recency of last birth.  
Information on both variables was collected during interview.  Number of full-term live births 
was grouped into three categories: nulliparous (reference), 1-2 children, and ≥3 children.  
Recency of last birth was calculated as the year of diagnosis minus the year of the last birth, and 
was grouped into four categories: 0 (reference), <5 years, 5-<10 years, and ≥10 years.  
3.2.2. Breast cancer subtype assessment and definition 
The CBCS used the most frequently-used IHC classification criteria developed by 
Nielsen and colleagues (55), where luminal A tumors are defined as ER+; either PR+ or PR-; and 
Her2-.  Luminal B tumors are defined the same as luminal A for ER and PR but differ in positive 
Her2 expression.  Her2-positive tumors are defined by the lack of expression of ER and PR and 
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the presence of HER2 receptor (ER-/PR-/Her2+).  BLBCs are defined by the lack of ER, PR and 
Her2, and the expression of CK5/6+.   
To evaluate ER/PR status, tumor blocks were sectioned and stained for a panel of IHC 
markers at the Immunohistochemistry Core Laboratory at UNC-Chapel Hill.  ER and PR status 
were obtained from medical records for 80% of invasive cases.  For ER/PR information from 
medical records, the status was determined in various clinical laboratories, the vast majority 
using an IHC method with cutoffs for receptor positivity ranging from more than 0 to more than 
20 percent for assays performed on paraffin-embedded tissues (about half) and of 10 or 15 
fmol/mg for assays performed on frozen tissues (about half).  For 11% of the cases with missing 
status for ER/PR on medical records, ER/PR status was determined at the UNC laboratory.  
ER/PR status was missing for the remaining 9 percent of the cases (41, 200, 204).  The staining 
of Her2 was categorized using a 0 to 3 scoring system, and assignment of Her2 positivity was 
defined as any Her2 staining (41, 204).  CK 5/6 was scored positive if any cytoplasmic and/or 
membranous staining was seen (200, 205).  Compared to cases excluded from subtype analyses, 
cases included in subtype analyses were less likely to be stage I (39% vs. 48%) and more likely 
to be stage II (51% vs. 39%), with little differences observed in stage III (8% vs. 10%) or stage 
IV (3% vs. 4%).  There were no differences between the included and excluded cases in age, 
race, menopausal status, lymph node status, nuclear grade, histologic grade, or survival (41, 76, 
201). 
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3.2.3. Breast cancer-specific survival and overall survival assessment 
The National Death Index provided vital status and dates of deaths on the CBCS cases 
through December 31, 2011.  Deaths among cases were determined using weighted probabilistic 
scores and predetermined matching cutoffs to establish a maximum of 1 match per individual.  
These data were derived from death certificates and included all causes of death for overall 
survival and breast cancer-specific survival with high sensitivity (98%) and specificity (100%) 
(206).  International Classification of Diseases (ICD) breast cancer codes 174.9 (ICD-9) or C50.9 
(ICD-10) were used to identify deaths due to breast cancer on the death certificate.  The main 
outcome of interest in our survival analysis is time to death, which is defined as the number of 
years between breast cancer diagnosis and death from breast cancer or any cause.  Women alive 
at the end of follow-up or the last known follow-up date were considered censored in overall 
mortality analyses.  In the cause-specific mortality analyses, women who died from causes other 
than breast cancer were additionally counted as censored.  
3.2.4. Effect modification 
Besides intrinsic subtype, race and menopausal status were considered as potential effect 
modifiers.  Race was based on self-report at the time of in-person interviews.  The two races 
included in this project were White and African American.  Menopausal status was determined 
using information from the interview.  Women younger than 50 years who had undergone 
natural menopause, bilateral oophorectomy, or irradiation to the ovaries were classified as 
postmenopausal; otherwise they were classified as premenopausal.  For women aged 50 or older, 
menopausal status was assigned based upon cessation of menstruation.  Considering that there is 
no standard definition for menopausal status and the small sample size of perimenopausal 
women (n=95), perimenopausal women were excluded to avoid misclassification (n=95).    
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3.2.5. Confounding 
Potential confounders were selected based on the available literature and conceptual 
diagrams/directed acyclic graphs (DAG) as shown in Figure 3.1 and Figure 3.2.  Reproductive 
factors other than parity (breastfeeding, age at first menarche, age at first birth, and age at last 
birth) were not be considered as confounders because they are not up-stream factors and 
literature review suggested no association between these reproductive factors and breast cancer 
prognosis.  Although tumor characteristics were not up-stream factors of obesity/parity, they 
were adjusted in the model building process to account for fundamental differences in tumors not 
captured by intrinsic subtype, and also to minimize bias due to the missing information on 
treatment.  More details on measurement and definition of potential confounders are listed in 
Table 3.1.   
3.2.6. Statistical methods 
The associations of obesity/parity with prognosis were evaluated separately.  Survival 
curves by obesity/parity categories were be generated using the Kaplan-Meier method.  The log-
rank test was used to test whether there was a difference between categories in the probability of 
death at any time.  To estimate the size and precision of differences in survival between 
obesity/parity categories, we performed univariate Cox regression to estimate hazard ratios and 
corresponding confidence intervals (obesity: BMI<25kg/m2 and the first tertile of WHR as 
reference categories; number of live birth and birth recency: nulliparous as references).  The 
interpretation of a HR was the relative risk of death comparing those who were exposed to some 
characteristic to those who were not, over the entire study period.   
Kaplan-Meier survival curves, log-rank tests, and Cox regression are based on the 
assumption that censoring is non-informative and unrelated to prognosis.  In other words, the 
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people who are censored at some point in time are representative of those subjects who survive 
up to that point in time, conditional on explanatory variables (207, 208).  This assumption of 
censoring was unlikely to be violated in the CBCS, as patients entered the study based on their 
date of diagnosis, and date and cause of death were obtained from the National Death Index 
without knowledge of obesity/parity.  Therefore, in this proposed project, it was unlikely that 
informative censoring was a large source of bias.  Another important assumption for log-rank 
tests and Cox regression is that the ratio of survival probabilities between compared groups does 
not depend on time.  This assumption was evaluated using Kaplan-Meier survival curves and 
log-log plots of survival.  In addition, a separate model was used with the inclusion of a time-
dependent cross-product term for the natural log of survival time (days) and the covariate of 
interest.  The assumption was considered to hold if the interaction term is not significant at p ≥ 
0.05.   
Effect modification by intrinsic subtype was initially assessed by examining stratum-
specific estimates.  It was also evaluated by including the product interaction terms.  If the p 
value for the likelihood ratio test comparing models with and without the interaction term(s) was 
<0.10, then effect modification was considered significant on a multiplicative scale.  The results 
of stratified analyses were presented no matter how intrinsic subtype tests as a significant effect 
modifier.  The effect modifications of race and menopausal status were also evaluated only 
within luminal and basal-like tumors using similar approaches.  
Variables listed in Table 3.1 were examined as potential confounders.  Models were built 
based on types of potential confounders: modeling started with exposure, age, race, and study 
phase; proceeded to adjustment for identified potential confounders; and finally included 
adjustment for tumor characteristics.   
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Table 3.1: Measurement and definition of potential confoundersa 
Variables Measurement Code in statistical analysis 
Age at diagnosis  Collected during interview Continuous and categorical (<40, 
40-49, 50-59, or ≥60)  
Parityb Collected during interview 0, 1-2, 3+ 
Family history of breast 
cancer (first degree) 
Collected during interview Categorized as yes or no  
Education Collected during interview Categorized as high school and post 
high school, college and above, or 
lower than high school 
Family income Collected during interview Categorized as 15-30K, 30-50K, 
>50K, or <15K. 
Smokingb Collected during interview Categorized as never, former, or 
current 
Physical activityb Collected during interview Categorized as yes or no 
HRT Collected during interview Defined as any hormone 
replacement therapy and 
categorized as never user, current 
user, or past user 
OC Collected during interview Categorized as never or ever, where 
ever user was defined as 3+months 
of OC use before BC diagnosis.  
Lymph node status Extracted from medical record Categorized as positive or negative 
Tumor stage 
(Nottingham) 
Extracted from medical record Based on the American Joint 
Committee on Cancer (AJCC, 5th 
edition), categorized as I, II, or 
III+IV 
Nuclear grade Extracted from medical record Categorized as marked 
pleomorphism or slight/moderate 
Histologic grade Evaluated in participating hospitals 
based on the H&E slides prepared at 
UNC 
Categorized as poorly 
differentiated, or well/moderately 
differentiated 
Histology group Evaluated in participating hospitals 
based on the H&E slides prepared at 
UNC 
Categorized as ductal or others 
Mitotic index Extracted from medical record Categorized as high if index is 
greater than 10 mitotic 
figures per 10 high-power fields; 
otherwise as low 
a The definition of race and menopause was described in 4.2.4. 
b Considered as potential confounders in Aim 1 (obesity association). 
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Figure 3.1: Diagram illustrating associations of obesity, intrinsic subtype, breast cancer 
outcome, and other related factors 
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Figure 3.2: Diagram illustrating associations of parity, intrinsic subtype, breast cancer 
outcome, and other related factors 
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 CHAPTER 4: PARITY AND BREAST CANCER SURVIVAL 
4.1. Background 
Reproductive history is an important established determinant of breast cancer risk.  
Increased appreciation of etiologic heterogeneity in breast cancer has added complexity to our 
current understanding of the associations.  Risk of basal-like breast cancer and triple-negative 
breast cancer is suggested to increase with multiple births and recency of last birth/pregnancy 
(69-71, 73, 76, 81, 141), while risk of luminal tumors follows patterns established for breast 
cancer overall.  These results suggest that pregnancy and associated events may have contrasting 
mechanistic effects, including increasing short term risk for some intrinsic molecular tumor 
subtypes, while providing long-term protection against others. 
The proposed biological mechanisms linking parity and increased basal-like/ triple-
negative breast cancer risk include increased hormonal stimulation, expansion of stem/progenitor 
cells, growth stimuli, and pro-inflammatory and wound-healing changes in microenvironment 
during breast involution (137-139, 209, 210).  These mechanisms could influence both risk and 
prognosis, although the latter issue has not been well studied.  
It remains unsettled whether parity has prognostic value in breast cancer.  While some 
studies reported no association between number of births and prognosis (88, 145-156), other 
studies reported that multiple births was associated with a poorer prognosis (155, 157-164), and 
still others showed improved prognosis among multiparous women (149, 165, 166).  These 
discrepancies may be attributed to different distributions of potential effect measure modifiers 
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such as race and menopausal status, and a different profile of the intrinsic subtype across study 
populations.  Results regarding time since last birth are relatively consistent.  Recent birth 
appears to be associated with poor outcome among breast cancers overall (157, 167, 170, 171).  
Little is known whether the influence of recent birth on prognosis varies by subtype.  
Using data from the Carolina Breast Cancer Study (CBCS), a large population-based case-
control study, we assessed the impact of multiparity and recent birth, on overall and breast 
cancer (BC)-specific survival.  These associations were evaluated among breast cancers as a 
whole and in strata defined by specific breast cancer subtypes (basal-like and luminal). 
4.2. Methods 
4.2.1. Study population 
The CBCS is a population-based case-control study, the details of which have been 
described previously (76, 200).  Briefly, a total of 1,808 patients aged 20-74 years diagnosed 
with primary invasive breast cancer during 1993-1996 (Phase I) and 1996-2001 (Phase II) were 
identified using rapid case ascertainment from NC Central Cancer Registry, with African 
American and young cases (aged 20-49 years) oversampled using randomized recruitment (200, 
211).  Participants were interviewed in person within 1 year of the diagnosis by trained nurses 
who collected anthropometric measurements and questionnaire responses.  Clinicopathological 
information was abstracted from clinical records and pathological reports.  The study procedures 
for recruitment and enrollment into the CBCS were approved by the Institutional Review Board 
of the University of North Carolina (UNC).  All study participants gave written informed 
consent.   
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4.2.2. Breast cancer subtype classification 
The details of breast cancer subtyping have been published previously (41, 76).  Briefly, 
whole, formalin-fixed paraffin-embedded tumor tissues were sectioned and stained for a panel of 
immunohistochemical (IHC) markers in the IHC Core Laboratory at UNC.  The following 
markers were used to determine breast cancer intrinsic subtypes: luminal A (ER+ and/or PR+, 
HER2-), luminal B (ER+ and/or PR+, HER 2+), basal-like (ER-, PR-. HER2-, HER1+ and/or 
cytokeratin 5/6+), HER2-enriched (ER-, PR-, HER2+), and unclassified (negative for all five 
markers).  We combined luminal A and luminal B as luminal tumors due to the small number of 
luminal B tumors (n=111) and, more importantly, recent revisions to the IHC definition of 
luminal B (35, 57).  Luminal A and B tumors cannot be reliably distinguished without additional 
markers (such as Ki-67) or nanostring data (212).  In the CBCS, the demographic and tumor 
characteristics in patients with luminal A and B tumors were comparable except luminal B 
tumors more likely to be lymph node positive (p=0.01). 
4.2.3. Exposure and outcome assessment 
Parity status was evaluated as number of full-term births.  Recency of last birth was 
calculated as the year of diagnosis minus the year of the last full-term birth.  Their values were 0 
for nulliparous women.  
Linkage with the National Death Index provided vital status, dates of deaths, and cause of 
death on the CBCS cases through December 31, 2011. Deaths among cases were determined 
using weighted probabilistic scores and predetermined matching cutoffs to establish a maximum 
of 1 match per individual (206).  International Classification of Diseases (ICD) breast cancer 
codes 174.9 (ICD-9) or C50.9 (ICD-10) were used to identify deaths due to breast cancer on the 
death certificate.   
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4.2.4. Statistical analysis 
The current analysis was limited to 1,140 African American or White patients (9 other 
race cases excluded) with available information on intrinsic subtype (659 cases without subtype 
information excluded), parity, and birth recency.  The demographic and tumor characteristics of 
the excluded cases were compared with those of the included cases; no significant differences 
were detected, except that  excluded cases were less aggressive (more likely to have negative 
lymph node status, tumor size ≤ 2cm, and stage I).  After referring categorization of previous 
studies (76, 160, 171) and the distribution in this study population, number of full-term live 
births was grouped into three categories: nulliparous, 1-2 births, and ≥3 births.  Birth recency 
was grouped into four categories: nulliparous, <5 years, 5-<10 years, and ≥10 years.  To describe 
the characteristics of the study population, the distribution of age at diagnosis, menopausal 
status, race, BMI, WHR, family history of breast cancer, education, family income, smoking, 
alcohol intake, physical activity, the usage of hormone replacement therapy (HRT) and oral 
conceptive (OC), lymph node status, intrinsic subtype, tumor size, tumor stage, histology type, 
nuclear grade, histologic grade, and mitotic index, were evaluated by multiparity and birth 
recency categories by Chi-square test or Student’s t-test (Table A.1 and Table A.2).  The 
assessment and definition of these variables have been described previously (76).  Patients living 
as of December 31, 2011 were censored, and those who died of causes other than breast cancer 
were censored for BC-specific analysis.  Kaplan-Meier survival curves and log-rank tests were 
used to compare the difference in overall and BC-specific survivals by multiparity and birth 
recency.  
Cox regression analysis was used to estimate hazard ratio (HR) and 95% confidence 
interval (CI) for overall death and BC-specific death, with nulliparous as the reference.  Model 
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adjusted for study design factors (including age, race, and study phase) was considered as the 
primary model.  Then education and family income were adjusted as potential confounders based 
on selection with the aid of a directed acyclic graphs using on a priori knowledge.  Lastly, tumor 
characteristics, including tumor stage, tumor size, lymph node status, and histological type, were 
additionally adjusted to evaluate the influence of other prognostic factors on the associations of 
interest.     
Stratified analyses were performed to evaluate the effect modification by intrinsic 
subtype.  Only basal-like and luminal strata are presented because unclassified tumors are of 
biologically uncertain subtype and because too few patients (n=73) were HER2-enriched for 
stable estimation.  The difference in the hazard ratios by race and menopausal status within 
luminal and basal-like tumors was also assessed.  In the analysis by menopausal status, 
perimenopausal women were excluded to avoid misclassification (n=95).  In addition, because 
studies have suggested that factors predicting survival in early years after diagnosis may differ 
from those in later years (e.g. with tumor biological and pathologic characteristics dominant in 
early years and lifestyles dominant in later years (213)), analyses were conducted conditional on 
follow-up length: data were truncated at five years to evaluate five-year mortality and then 
survival was assessed conditional upon surviving the first five years.  Exploratory analyses were 
conducted to characterize the dose-response relationship of multiparity and birth recency with 
mortality.  In addition, to assess the potential interactions of breastfeeding-multiparity or 
multiparity-birth recency, compound variables were created and their corresponding HRs were 
calculated (breastfeeding-multiparity: nulliparous, 1-2 births and ever breastfed, 1-2 births and 
never breastfed, 3+ births and ever breastfed, and 3+ births and never breastfed; multiparity-birth 
 47 
 
recency:  nulliparous, 1-2 births and last birth <10 years, 1-2 births and last birth ≥ 10 years, 3+ 
births and last birth <10 years, and 3+ births and last birth ≥ 10 years). 
The proportional hazards assumption in each Cox model was assessed using log-log plots 
of survival and time-dependent cross-product terms of the survival time (years) and the variables 
of interest, and showed no violation of the assumptions.  All statistical tests were two sided with 
α=0.05, all analyses were performed using SAS version 9.2 (SAS Institute), and all figures were 
generated using R 3.0.0. 
4.3. Results 
4.3.1. Patient and tumor characteristics  
Among 1,140 breast cancer patients in this study, the average age at diagnosis was 51 
years (SD=11.5 years, range=23-74 years).  Approximately half of patients were African 
American (45%) and premenopausal (49%) per the sampling strategy of CBCS.  A total of 967 
(85%) women were parous, among which 416 (43%) had 3 or more births.  165 (17% of parous 
patients) had last full term birth within 10 years of breast cancer diagnosis.  The patient 
demographics by multiparity and by birth recency were detailed in Table A.1 and Table A.2, 
respectively.  Compared with nulliparous patients, patients with high parity (3+ births) were 
significantly older, and were more likely to be African American, obese (BMI≥30 kg/m2), lower 
socioeconomic status (SES) (measured by education and family income), alcohol abstainers, and 
non-OC users.  Patients with high parity (3+ births) also tended to have last birth more than 10 
years previous to diagnosis.  Consequently, birth recency was associated with similar 
characteristics as multiparity.  Additionally, patients who had given birth 10 years more before 
breast cancer diagnosis were more likely to be smokers and HRT users than patients with last 
birth within 5 years.   
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Luminal tumors comprised the majority of breast cancers (n=731, 64%), followed by 
basal-like tumors (n=205, 18%), unclassified (n=131, 11%), and HER2-enriched tumors (n=73, 
6%).  Compared with nulliparous patients, parous patients were more likely to have basal-like 
(frequency was highest in women with birth within 5-<10 years) and lymph node positive tumors 
(Table A.1 and Table A.2).  Among parous patients, lymph node positive and poorly 
differentiated tumors were more frequent in women with recent birth (<5 years). 
4.3.2. Associations of multiparity and birth recency with prognosis  
The median follow-up time was 13.5 years, ranging from 0.2 years to 18.7 years.  By the 
end of follow-up (December 31, 2011), there were 450 deaths, with 61% due to breast cancer 
(n=276).  Among breast cancer deaths, 159 (58%) had occurred within 5 years of diagnosis, and 
78 (28%) deaths occurred between 5 and 10 years.  Patients with higher parity tended to have 
poorer overall and BC-specific survival (overall, Figure B.1; BC-specific, Figure B.2).  In 
patients with three or more births, compared with nulliparous patients, the HR was 1.77 (95% 
CI=1.18-2.66) for BC-specific mortality after adjusting for age, race, and study phase (Table 
A.3), while the difference in overall mortality disappeared (HR=1.09, 95% CI=0.82-1.45, Table 
A.4).  Birth recency was only showed association with BC-survival, with HR of 1.83 (95% 
CI=1.07-3.13, reference=nulliparous) for women who gave birth within <5 years before 
diagnosis (HR adjusted for age, race, and study phase, Table A.3; survival curves, Figure B.2).  
When modeling parity as continuous variables, the risk for BC-specific mortality increased by 
10% (HR=1.10, 95% CI=1.03-1.18, p trend <0.01) for each additional birth, while no significant 
linear association detected for birth recency.  The magnitude of associations of multibirth and 
birth recency with BC-specific survival remained similar after adjusting for education and family 
income (parity3+, adjusted HR=1.76, 95% CI=1.13-2.73; recency <5 years, adjusted HR=1.90, 
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95% CI=1.10-3.34), but were attenuated after further adjustment for tumor characteristics 
(parity3+, adjusted HR=1.42, 95% CI=0.91-2.23; recency <5 years, adjusted HR=1.37, 95% 
CI=0.77-2.45).   
In stratified analyses, multiparity and birth recency showed distinct associations by 
intrinsic subtype (Figure B.2).  Consistent with results among all cases, no association of 
multiparity and birth recency with overall survival was detected in either luminal or basal-like 
tumors, except that birth within 10 years suggested a poor outcome in patients with luminal 
tumor (Table A.4).  Higher parity and more recent birth predicted poorer BC-specific survival, 
with a stronger association observed in luminal tumors than in basal-like tumors, although HR 
estimates in basal-like tumors were imprecise (Table A.3).  These associations found in both 
subtypes were independent of age, race, and SES factors, but were attenuated after adjustment 
for tumor characteristics.  Only among luminal tumors did birth recency remain significantly 
associated with BC-specific survival independent of tumor characteristics (adjusted HR=2.35 for 
last birth < 5 years, 95% CI=1.05-5.27, reference=nulliparous).  
We further evaluated stratified HRs according to follow-up period, menopausal status, 
and race.  Compared with effect estimates for the first five years, HRs for BC-specific survival 
were suggested to be greater after conditioning on survival to 5 years, particularly among 
patients with luminal tumors (Table A.5).  No significant differences were detected by 
menopausal status or race, although a stronger effect of birth recency was suggested in White 
women with luminal tumors.  
We explored the combined effect of multiparity and birth recency on breast cancer 
prognosis.  As presented in Figure B.3, after adjustment for age, race, study phase, and SES 
factors, parous patients with parity ≥ 3 births and recency < 10 years had the worst prognosis 
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(adjusted HR=2.02, 95% CI=1.09-3.73; reference=nulliparous), followed by patients with parity 
1-2 births and recency < 10 years (adjusted HR=1.69, 95% CI=1.06-2.67) and parous patients 
with recency ≥ 10 years (parity ≥ 3 birth and recency ≥ 10 years: adjusted HR=1.47, 95% 
CI=0.87-2.50; parity 1-2 birth and recency ≥ 10 years, adjusted HR=1.42, 95% CI=0.92-2.21), 
and nulliparous patients had the best prognosis.  The influence of breastfeeding was also 
evaluated (Figure B.4), and no significant modification of hazard ratios by breastfeeding status 
was observed (Figure B.5).  
4.4. Discussion 
In this study, patients with high parity or recent birth had worse BC-specific survival 
compared to nulliparous patients.  This association was independent of age, race, and SES 
factors, and was attenuated, but not fully explained by tumor characteristics.  No effect measure 
modification by race or menopausal status was detected among luminal tumor patients or basal-
like tumor patients.  The influence of parity and birth recency varied by intrinsic subtype and 
follow-up period, with stronger effects observed in long-term survivors (i.e. among those with 
survival ≥ 5 years) and in patients with luminal tumors.   
Birth recency, defined as time interval from last birth until diagnosis, has consistently 
been related to deleterious tumor characteristics (e.g. advanced stage, high histological grade, 
and high proportion of hormone receptor-negative tumors) (141, 162, 170, 174), and 
consequently poor prognosis (150, 153, 162, 163, 168-171).  Multiparity has also been associated 
with higher mortality, particularly BC-specific mortality (158, 165).  The current findings are in 
line with previous studies, and confirm that this association is not strongly modified by race, 
with HRs that are similar between White and African American women (153).   
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While effects of multiparity and recency of birth are most often considered as separate 
dimensions of exposure, we considered the joint effects of these two variables.  Women with 
high parity and short time since last birth had the highest BC-specific mortality.  The combined 
effect of multiparity and recency was not equal to the productive effect of parity and recency 
(Figure B.3), which suggests an interaction between the two factors (214, 215).  These findings 
indicate that as quantitative and temporal measures of pregnancy respectively, multiparity and 
recency may influence the natural history of breast cancer through distinct pathways, yet likely 
also share some mechanisms.  Pregnancy is a complex factor.  More factors (e.g. breastfeeding, 
age at first birth, and interval between births) than number and recency of births, are likely to 
modify its role in breast cancer development and progression.  Our study provided a rough 
picture of the associations of parity and prognosis in the setting of intrinsic subtype.  To better 
characterize the complicated effect of parity, studies with large data using more subtle analysis 
approaches is definitely needed (216, 217). 
Most previous studies of parity and survival considered subtype (usually defined by 
hormone receptor status) as a confounder (163, 171, 173, 174).  However, the heterogeneous 
association of parity with breast cancer risk across intrinsic subtype indicates that the underlying 
mechanisms may be different for each subtype (69-71, 73, 76, 81, 141).  We found that 
multiparity and birth recency had weaker effects among patients with basal-like tumors than 
patients with luminal tumors.  The trend of decreased mortality risk with time since last birth has 
been reported previously (146, 150, 169, 170), and in our study was only observed in luminal 
tumor patients.  To our knowledge, only one previous study has examined the influence of 
multiparity and birth recency on mortality by breast cancer subtype (171).  This study was based 
on 526 young patients with invasive breast cancer (20-44 years) in Japan.  Although no 
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association between multiparity and mortality was detected, worse prognosis was observed in 
patients with more recent birth.  Similar to our results, this association was stronger in luminal 
tumor patients than for all breast cancer patients (HR for ≤2 years group=3.07 vs 2.19, 
reference=nulliparous).  Unfortunately, the very small sample size of triple negative tumors 
(n=79) and lack of subtype-specific markers for basal-like breast cancer hampered this study’s 
ability to make inferences about basal-like breast cancer.   
If the mechanism by which parity influences breast cancer risk is to shift tumors toward 
more aggressive characteristics at diagnosis, then the effect of parity variables on survival should 
be diminished upon adjustment for tumor characteristics or may vary temporally following 
diagnosis.  Factors influencing early survival may be more related to intrinsic tumor 
characteristics and subsequent treatment, while later survival may depend upon host factors.  
Thus, we adjusted for tumor characteristics and conducted survival analyses condition upon 
surviving the first five years.   In this study and others (163, 171, 173, 174), adjustment for tumor 
characteristics only modestly influences the effect of parity.  With regard to conditional survival, 
parity was most strongly related to the reduced survival among women who survived at least five 
years, with significant relationships confined to luminal tumors.  This suggests different 
biological mechanisms driving parity-associated survivorship in basal-like vs. luminal cancers. 
There are many mechanisms that have been proposed for pregnancy-associated breast 
cancer progression.  High level of pregnancy hormones is a plausible mechanism, given the 
influence of estrogen in breast cancer progression (210, 218-220).  Additionally, considering the 
relatively long latent period of breast tumors, the hormonal milieu of pregnancy may, as a 
selection force, change the course of the disease by stimulating growth and promotion of existing 
tumor cells.  This pathway is expected to specifically influence ER-positive tumors.  However, 
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this mechanism is less compelling for ER-negative tumors.  One potential explanation is that the 
frequency of basal-like tumor clones may be higher than luminal tumor clones in young women 
(221).  Alternatively, the post-partum /post-lactation involution is also widely accepted, wherein 
inflammatory changes that accompany involution may promote tumor progression (210).  Our 
previous research showed that parity-induced changes in microenvironment gene expression 
differed by ER status (222).  Thus, mechanisms may differ by ER status of tumors.  Pregnancy 
may have both hormonal and microenvironmental effects on ER-positive/luminal tumors (223).   
Our study should be interpreted in light of some limitations.  First, the CBCS oversampled 
young and African American patients, which resulted in a higher proportion of patients with 
basal-like tumors in our study population.  Even so, stratified analyses by subtype still suffered 
from small sample size and imprecise estimates, particularly when evaluating the association 
differences by race and menopausal status in basal-like tumors.  The study in HER2-enriched 
tumors was also underpowered.  In our analysis, we adjusted for several key determinants of 
therapy (e.g. age, lymph node status, and SES) (193, 194), however treatment data was not 
collected.  Treatment heterogeneity within tumor classes has likely increased our variation, 
however it is unlikely to bias our results substantially.  Finally, although the different biological 
features and prognosis have been establish in gene expression studies(224), classification of 
luminal A and B in epidemiologic studies remains problematic.  Recent data show that 
stratification of Luminal A vs. B using HER2 status (as has been done previously in the CBCS 
study) results in misclassification of both tumor types (212).  To avoid this misclassification, we 
combined luminal A and B in this analysis, which hampered investigating differences in 
prognostic association of parity in these two strata. 
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In conclusion, our study identified multiparity and birth recency as predictors of breast 
cancer outcome.  Moreover, our results deepen the understanding of parity-associated survival by 
suggesting that the effect of parity may vary by intrinsic subtype, which will help optimize 
subtype-specific treatment strategies to improve breast cancer survival.  Studies with large 
sample size of uncommon subtypes and known treatment profiles are needed to validate our 
findings and to further investigate the potential interaction of parity and treatment.   
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CHAPTER 5: OBESITY AND BREAST CANCER SURVIVAL 
5.1. Background 
The association between obesity and poor breast cancer survival has been well-studied.  
Based on the most recently published meta-analysis, compared to lean patients, obese patients 
had 41% and 35% higher risk for all-cause deaths and BC-specific deaths, respectively (225).  
Proposed mechanisms include adverse disease features, hormonal influences, chronic 
inflammatory microenvironment, adipokines, epithelial-mesenchymal transition, insulin and 
insulin growth factor axis, and comorbidities that may interfere with treatment (226-228).  
Considering the obesity epidemic in the United States (229, 230), obesity may become an 
important facet of cancer management, thus it is important to understand how obesity affects 
breast cancer survival. 
Despite wide acceptance of a plausible association between obesity and progression, 
inconsistent results are still observed across epidemiologic studies and population subgroups 
(225).  In a study of 4,538 breast cancer patients aged 35-64 years, obesity was associated with 
mortality in White but not African American women (231).  Another study among 
premenopausal women even observed a protective effect of obesity on BC-specific mortality 
(232).  One contributing factor of these inconsistent results may be failure to fully account for 
breast cancer subtype.  Obesity shows distinct relationships with risk of specific breast cancer 
subtype (46, 73, 77, 81).  The same molecular mechanisms active during etiology may also 
promote progression in some subtypes.   Previous studies investigating this hypothesis have 
primarily defined subtype by hormone receptor status (estrogen receptor, progesterone receptor, 
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or both), and these studies have also had inconsistent findings (120).  A meta-analysis suggested 
that the influence of obesity may be stronger in hormone receptor-positive tumors than hormone 
receptor-negative tumors (120).   
In recent years, it has been observed that ER-negative tumors are heterogeneous (25, 60).  
While ER-positive tumors are predominantly luminal subtype, strata defined by ER-negative 
status include a mix of tumors including HER2-positive, basal-like, and triple-negative tumors 
that are unclassifiable (25, 41).  However, few studies have examined obesity-associated survival 
by intrinsic subtype.  Among studies that have evaluated adiposity and survival by subtype, most 
have used only BMI as the primary obesity measure, and studies conflict on whether BMI or 
WHR may be more strongly linked with breast cancer subtypes (71, 76).  Data on central obesity 
(such as WHR) is rare in epidemiologic studies (113), despite the importance of this adiposity 
measure (233, 234).   
Using data from the Carolina Breast Cancer Study (CBCS), a large population-based 
case-control study, we assessed the impact of BMI and WHR on overall and breast cancer (BC)-
specific survival.  These associations were evaluated among breast cancers as a whole and in 
strata defined by specific breast cancer subtypes (basal-like and luminal). 
5.2. Methods 
5.2.1. Study population 
The CBCS is a population-based case-control study, the details of which have been 
described previously (76, 200).  Briefly, a total of 1,808 patients aged 20-74 years diagnosed 
with primary invasive breast cancer during 1993-1996 (Phase I) and 1996-2001 (Phase II) were 
identified using rapid case ascertainment from NC Central Cancer Registry, with African 
American and young cases (aged 20-49 years) oversampled using randomized recruitment (200, 
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211).  Participants were interviewed in person within 1 year of the diagnosis by trained nurses 
who collected anthropometric measurements and questionnaire responses.  Clinicopathological 
information was abstracted from clinical records and pathological reports.  The study procedures 
for recruitment and enrollment into the CBCS were approved by the Institutional Review Board 
of the University of North Carolina (UNC).  All study participants gave written informed 
consent.   
5.2.2. Breast cancer subtype classification 
The details of breast cancer subtyping have been published previously (41, 76).  Briefly, 
whole, formalin-fixed paraffin-embedded tumor tissues were sectioned and stained for a panel of 
immunohistochemical (IHC) markers in the IHC Core Laboratory at UNC.  The following 
markers were used to determine breast cancer intrinsic subtypes: luminal A (ER+ and/or PR+, 
HER2-), luminal B (ER+ and/or PR+, HER 2+), basal-like (ER-, PR-. HER2-, HER1+ and/or 
cytokeratin 5/6+), HER2-enriched (ER-, PR-, HER2+), and unclassified (negative for all five 
markers).  We combined luminal A and luminal B as luminal tumors due to the small number of 
luminal B tumors (n=111) and, more importantly, recent revisions to the IHC definition of 
luminal B (35, 57).  Luminal A and B tumors cannot be reliably distinguished without additional 
markers (such as Ki-67) or nanostring data (212).  In the CBCS, the demographic and tumor 
characteristics in patients with luminal A and B tumors were comparable except luminal B 
tumors more likely to be lymph node positive (p=0.01). 
5.2.3. Exposure and outcome assessment 
Waist circumference, hip circumference, height, and body weight were measured by 
trained nurses at the time of interview.  BMI was computed by dividing the weight in kilograms 
by the square of the height in meters.  The World Health Organization (WHO) definition was 
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used to classify patients as underweight (BMI <18.5 kg/m2), normal (BMI 18.5-24.9 kg/m2), 
overweight (BMI 25-29.9 kg/m2), and obese (BMI ≥30 kg/m2).  Underweight patients were 
combined with normal-weight patients due to small number (n=23, 2%).  WHR was calculated as 
the ratio of waist to hip circumference (cm).  Since the criteria for central obesity is not 
standardized (235), tertiles of the WHR distribution in CBCS controls (with cutoff points of 0.77 
and 0.83) were used (76).  
Linkage with the National Death Index provided vital status, dates of deaths, and cause of 
death on the CBCS cases through December 31, 2011. Deaths among cases were determined 
using weighted probabilistic scores and predetermined matching cutoffs to establish a maximum 
of 1 match per individual (206).  International Classification of Diseases (ICD) breast cancer 
codes 174.9 (ICD-9) or C50.9 (ICD-10) were used to identify deaths due to breast cancer on the 
death certificate.   
5.2.4. Statistical analysis 
Our analysis included 1,109 patients, after excluding 9 cases with race other than White 
or African American, 659 cases without immunohistochemical subtype information, and 31 
cases with missing data on anthropometric measures.  The demographic and tumor 
characteristics of the excluded cases were compared with those of the included cases; no 
significant differences were detected, except that  excluded cases were less aggressive (more 
likely to have negative lymph node status, tumor size ≤ 2cm, and stage I).  The demographic, 
lifestyle, clinical and other characteristics of the study population were evaluated by BMI and 
WHR using Chi-square test or Student’s t-test (Table A.7 and Table A.8).  The assessment and 
definition of these variables have been described previously (76).  Patients living as of December 
31, 2011 were censored, and those who died of causes other than breast cancer were censored for 
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breast cancer (BC)–specific analysis.  Kaplan–Meier survival curves and log-rank tests were 
used to compare the difference in overall and BC-specific survivals by BMI and WHR.   
Cox regression analysis was used to estimate the hazard ratio (HR) and 95% confidence 
interval (CI) for overall death and BC-specific death, with BMI <25 kg/m2  or bottom WHR 
tertile as the reference category.  Confounders were selected based on a priori knowledge and 
with the aid of a directed acyclic graph.  To understand the influence of confounders on the study 
associations, we added these covariates sequentially.  Multivariable models included a minimal 
model (age, race, and study phase; Model 1), then a model additionally adjusted for selected 
socioeconomic factors (education and income) and lifestyle factors (smoking, alcohol intake, 
physical activity, and parity; Model 2), and finally, a model adjusted for tumor characteristics 
(tumor stage, tumor size, lymph node status, and histological type; Model 3).   
Stratified analyses were performed to evaluate effect modification by intrinsic subtype.  
Only basal-like and luminal strata are presented because unclassified tumors are of biologically 
uncertain subtype and because too few patients (n=73) were HER2-enriched for stable 
estimation.  The difference in HRs by race and menopausal status within luminal and basal-like 
tumors was also assessed.  In the analysis by menopausal status, perimenopausal women were 
excluded to avoid misclassification (n=95).  In addition, because studies have suggested that 
factors predicting survival in early years after diagnosis may differ from those in later years (e.g. 
with tumor biological and pathologic characteristics dominant in early years and lifestyles 
dominant in later years (213)), analyses were conducted conditioned on follow-up length: data 
were truncated at five years to evaluate five-year mortality and then survival was assessed 
conditional upon surviving the first five years. 
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The proportional hazards assumption in each Cox model was assessed using log-log plots 
of survival and time-dependent cross-product terms of the survival time (years) and the variables 
of interest, and showed no violation of the assumptions.  All statistical tests were two sided with 
α=0.05, all analyses were performed using SAS version 9.2 (SAS Institute), and all figures were 
generated using R 3.0.0. 
5.3. Results 
5.3.1. Patient and tumor characteristics  
Among 1,109 breast cancer patients in this study, the average age at diagnosis was 51 
years (SD=11.5 years, range=23-74 years).  Approximately half of patients were African 
American (45%) and premenopausal (42%).  The mean BMI for the entire study population was 
28.5 kg/m2 (SD=6.9 kg/m2, range=14.3-57.9 kg/m2), with 37% (n=410) considered obese.  The 
mean WHR was 0.82 (SD=0.08, range=0.60-1.34), with 36% (n=399) considered obese with a 
WHR≥0.85 (cutoff recommended by WHO) (236).  Consistent with previous reports (237), BMI 
and WHR showed relatively low correlation (Pearson’s r=0.40, p<0.01) and low agreement for 
obese classification (kappa coefficient=0.32, p<0.01).  However, patient demographics showed 
similar distribution by BMI and WHR categories (Table A.8 and Table A.7).  Patients with 
higher BMI or WHR tended to be older, African American, alcohol abstainers, lower 
socioeconomic status (SES) (measured by education and family income), OC users, and have 
more births.  In addition, the high WHR group (≥0.84) had a higher proportion of current 
smokers.     
Luminal tumors comprised the majority of breast cancers (n=714, 64%), followed by 
basal-like tumors (n=197, 18%), unclassified (n=126, 11%), and HER2-enriched tumors (n=72, 
6%).  Higher adiposity level (both BMI and WHR) was significantly associated with higher 
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prevalence of basal-like tumors, but lower prevalence of luminal tumors (Table A.8 and Table 
A.7).  Moreover, high mitotic index was more prevalent among patients with a BMI of 25-<30 
kg/m2 (p=0.02).  Compared with BMI, WHR was more related to tumor characteristics, with high 
WHR group (≥ 0.84) having higher prevalence of large (>5cm, p<0.01) and high stage (stage 
III&IV, p=0.01) tumors. 
5.3.2. Associations between obesity and prognosis  
The median follow-up time was 13.5 years, ranging from 0.2 years to 18.7 years.  By the 
end of follow-up, there were 435 deaths, and 62% of deaths were due to breast cancer (n=268).  
Among breast cancer deaths, 155 (58%) occurred within 5 years of diagnosis, and 76 (28%) 
occurred between 5 and 10 years.  Patients with high BMI or WHR had poorer overall survival 
(p-value for log rank test<0.01, Figure B.6).  The survival difference by BMI group became 
insignificant and smaller after adjusting for age, race, study phase, SES factors, and lifestyle 
factors (BMI ≥30 kg/m2 vs. <25 kg/m2,adjusted HR=1.19, 95% CI=0.91-1.55, Table A.8), and 
was further reduced after further adjusting for tumor characteristics (adjusted HR =1.11, 95% 
CI=0.84-1.45).  Compared with BMI, WHR showed a stronger association with all-cause 
mortality, which was independent of potential confounders (WHR ≥ 0.84 vs. <0.77, adjusted 
HR=1.50, 95% CI=1.11, 2.05), but was attenuated after further adjustment for tumor 
characteristics (adjusted HR=1.25, 95% CI=0.91-1.72).  Associations of obesity with BC-
specific mortality were weaker than those with overall mortality (p-value for log rank tests were 
0.20 and 0.15 for BMI and WHR, respectively; Figure B.7), and were not detected in 
multivariate analyses (Table A.9).  
In subtype-stratified analyses, BMI and WHR demonstrated different prognostic 
association by subtype.  As shown in Figure B.6, among patients with basal-like tumors there 
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was a significant difference in overall survival by BMI, independent of potential confounders 
and tumor characteristics (Table A.8, BMI≥30 kg/m2 vs <25 kg/m2, adjusted HR=2.04, 95% 
CI=1.01-4.13).  This difference remained after adjustment for WHR (adjusted HR=2.57, 95% 
CI=1.20-5.54).  In contrast, WHR had a stronger influence on all-cause mortality in patients with 
luminal tumor (WHR ≥0.84 vs. <0.77, adjusted HR=1.75, 95% CI=1.20-2.56).  Although this 
association cannot be explained by BMI (HR adjusted for BMI=1.79, 95% CI=1.20-2.68), it was 
not independent of tumor characteristics (HR additionally adjusted for tumor 
characteristics=1.33, 95% CI=0.89-1.97).  
We further evaluated subtype-specific HRs according to follow-up period, menopausal 
status, and race.  The influence of obesity on all-cause mortality appeared stronger among 
patients who survived at least 5 years after diagnosis, particularly among patients with basal-like 
tumors (Table A.10, BMI≥30 kg/m2, adjusted HR=3.15, 95% CI=1.13-8.79).  No significant 
differences were detected by menopausal status or race, although the association of WHR 
showed some suggestion of modification by menopausal status and race among basal-like cases 
(Figure B.8), with HRs higher in postmenopausal and White patients. 
5.4. Discussion 
Our study was in agreement with previous reports of an association between BMI or WHR 
and all-cause mortality among breast cancer cases overall (119, 225, 238).  The association with 
all-cause deaths was independent of age, race, lifestyle and SES factors, and was attenuated, but 
not fully explained by tumor characteristics.  Interestingly, the influence of obesity on all-cause 
mortality varied by intrinsic subtype and obesity measure.  While BMI predicted mortality in 
patients with basal-like tumors, WHR predicted mortality in patients with luminal tumors.  The 
association between these measures and breast-cancer specific survival was not significant. 
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A few previous studies have assessed the relationship between obesity and breast cancer 
prognosis by intrinsic or molecular subtype (66, 121-125, 239), and these have suggested a 
heterogeneous effect of obesity.  Five studies examined BMI in triple negative breast cancer 
(TNBC) (66, 121-125).  One study in premenopausal women reported increased BC-specific 
mortality associated with obesity (obese vs normal BMI: HR=1.4, 95% CI=1.0-2.1) among 
TNBC, but not among luminal tumors (66).  In another study of TNBC cases among 
predominantly African American women, and including both pre- and post- menopausal women, 
BMI was associated overall survival (HR=1.36, 95% CI=0.77-2.42), but not relapse-free survival 
(HR=1.01, 95% CI=0.67-1.52) (123).  The other three studies, with a majority of White women 
(both pre- and post-menopausal), did not detect any association between BMI and breast cancer 
prognosis among TNBC (121, 122, 124).  Although the sparse data and differences in population 
characteristics and covariates limits direct comparison across these studies, our results seem 
relatively consistent with the findings of previous studies with high proportions of young or 
African American patients. These findings suggest that the prognostic association of obesity may 
vary by age and race. However, the sample size of our study and previous studies was not large 
enough for multi-stratified analysis. 
Previous studies have reported a general larger effect of BMI on overall survival than the 
effect on BC-specific mortality (225), suggesting that non-cancer causes of death contribute to 
the less favorable outcomes noted for obese patients.  However, our study, consistent with some 
studies (117, 121, 123, 126, 127), did not observe an association of obesity and BC-specific 
mortality.  Based on two large studies (n=18,967 (156) and n=14,709 (240), respectively), 
obesity was not associated with loco-regional recurrence (156, 240) and five-year distant 
metastases (156).  Loco-regional recurrence and metastases are strong predictors for BC-specific 
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mortality, and are more frequently observed in basal-like tumor patients and African American 
patients (44, 92), which may contribute to the null association in the CBCS where the two 
subpopulations were over-represented.  Obese patients are more likely to have comorbidities and 
tend to die from non-cancer causes before they die from breast cancer.  When the “unhealthy” 
obese people die from non-breast cancer causes, they are deprived the opportunity to die from 
breast cancer.  The obese women left in the risk population for BC-specific mortality are 
“healthy” and do not possess disadvantages in BC-specific survival compared with non-obese 
patients.  Therefore no association between obesity and breast cancer mortality will be observed.    
BMI and WHR are the most commonly used anthropometric measures of general obesity 
and central obesity, respectively.  There is an increasing body of evidence that different adipose 
tissue depots (e.g. visceral and subcutaneous adipose tissue) differ in both cellular composition 
and physiology, resulting in distinct roles in disease development and progression (241, 242).  
Generally visceral/abdominal adipose is considered more metabolically active, and plays more 
important roles in pathological processes.  This perspective is supported, albeit inconsistently, by 
epidemiologic data.  Compared with BMI, WHR/waist circumference was more strongly 
correlated with growth hormone, insulin growth factor (IGF)-1, insulin resistance, circulating 
estradiol fractions and leptin in postmenopausal women (243-245).  Paralleling differences in 
disease risk of diabetes and cardiovascular disease (246-249), differences in the effects of BMI 
versus WHR were also observed in studies of breast cancer risk (250).  When considering breast 
cancer as a whole, meta-analysis showed that BMI decreased risk of premenopausal breast 
cancer, but increased risk of postmenopausal breast cancer, while WHR was associated with an 
increased risk of both pre- and postmenopausal breast cancer (250).  In the CBCS, WHR, but not 
BMI, was independently associated with increased risk of luminal A in postmenopausal women, 
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and basal-like tumor in pre- and postmenopausal women (76, 251).  However, to our knowledge 
no previous studies have observed differential effects of WHR and BMI on basal-like or luminal 
breast cancer prognosis.   
Tumor characteristics may dominate early survival following diagnosis, with little 
opportunity for lifestyle factors to mitigate the effects of very aggressive tumor phenotypes.  
This idea is supported by a study where in the first 5 years after diagnosis, there was no 
association with BMI (HR=1.08, 95% CI=0.96-1.21), but from 5 to 10 years after diagnosis, the 
risk of developing distant metastases increased significantly (HR=1.46, 95% CI=1.11-1.92) 
(156).  In our study, we observed a similar increment of the association after 5 years.  
Particularly in basal-like tumors, their overall and BC-specific mortality HRs of BMI after 5 
years were 2 and 4 times the HRs in the first five years respectively (BC-specific mortality HRs 
were statistically insignificant and not shown in the paper).  Furthermore, there has been a 
paradox observed in triple-negative disease (84), such that triple-negative/basal-like patients with 
strong pathologic complete response have very favorable prognosis despite very high hazard 
rates in early years following diagnosis.  It may be that in this period when disease-specific 
mortality is lower for basal-like breast cancer, obesity is more influential for overall survival.  
This underscores that it remains important to study overall survival for breast cancer patients.  
Understanding the mortality risks of patients who have low risk of disease relapse are important 
for cancer survivors; patients who move from high to low risk of breast cancer relapse may move 
into a period where other comorbidities become a greater concern than breast cancer itself.   
Our study should be interpreted in light of some limitations.  First, the CBCS oversampled 
young and African American patients, which resulted in a higher proportion of patients with 
basal-like tumors in our study population.  However, even so, stratified analyses by subtype still 
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suffered from small sample size and imprecise estimates.  Second, obesity status in our study 
was assessed shortly after diagnosis (< 1 year).  Anthropometry is likely to change following 
diagnosis and treatment.  Based on an analysis of 12,915 breast cancer patients from four 
prospective cohorts, the mean weight change was 1.6 kg during a follow-up averaging 8.1 years 
(189).  This weight change during follow-up may not be large enough to induce considerable 
misclassification of obesity status.  Third, treatment data was not collected in Phases I and II of 
the CBCS, limiting our ability to study the effect of treatment-obesity interaction and treatment 
in comorbidities.  Finally, although distinct biological features and prognosis by subtype have 
been established in gene expression studies (224), classification of luminal A and B in 
epidemiologic studies remains problematic.  Recent data show that stratification of Luminal A 
vs. B using HER2 status (as has been done previously in the CBCS study) results in 
misclassification of both tumor types (212).  To avoid this misclassification, we combined 
luminal A and B in this analysis, which hampered investigating differences in prognostic 
association of obesity in these two strata. 
In conclusion, our study showed the association of adiposity and overall survival, while 
effects on breast cancer-specific survival are weak to null.  Moreover, different adiposity 
measures should be considered as each measure appears to be associated with different subtype 
and capture different biological characteristics.  Basal-like and luminal breast cancer patients, 
particularly those that have longer term survival, may have greater risk of mortality due to 
comorbidities associated with specific types of obesity.   
 67 
 
CHAPTER 6: DISCUSSION 
6.1. Main findings  
In this cohort study of 1,140 patients with invasive breast cancer from the Phase I and II of 
the CBCS study, we evaluated the influence of parity and obesity on overall and BC-specific 
survival.  Parity (measured by number of full-term birth and recency of last birth) was 
significantly associated with poor BC-specific survival, while obesity measures (BMI and WHR) 
were significantly associated with poor overall survival.  These associations were independent of 
age, race, SES factors, and lifestyle factors (in obesity analysis), although the associations were 
attenuated after adjusting for tumor characteristics.   
The influence of parity and obesity on prognosis was distinct for basal-like and luminal 
tumors.  Both multiparty and birth recency had stronger effect on breast cancer-specific survival 
among luminal patients than among basal-like patients.  High BMI (≥30 kg/m2) was associated 
with higher all-cause mortality among patients with basal-like tumor, while high WHR (≥0.84) 
was associated with higher mortality among patients with luminal tumor.   
It has been argued that the first few years of survivorship are determined most strongly by 
tumor characteristics, while the effects of behavioral or other patient characteristics may play a 
stronger role five or more years after diagnosis (213).  Our study provides some evidence for this 
pattern, with more pronounced effects of parity and obesity conditioning upon survival to 5 years 
post-diagnosis.   
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6.2. Biological hypotheses for distinct parity- and obesity-associated survival by subtype 
The prognostic influence of parity and obesity in breast cancer has been reported 
previously, and the underlying mechanisms are proposed and reviewed (138, 210, 226, 228).  
However, biological explanations for their different effect by intrinsic subtype are under-
explored.  
The association of parity with breast cancer is complex, and the underlying biological 
basis is likely through multiple pathways.  In the long run, parity confers a protection against the 
development of breast cancer by inducing differentiation and apoptosis of mammary stem cells 
(252).  However, it also has a possible promoting effect on breast cancer (218, 253).  High levels 
of pregnancy hormones may change the course of the disease, acting as a selection force by 
stimulating growth and promotion of existing tumor cells.  Likely, this hormone-related pathway 
specifically influences ER-positive tumors.  This hormone-drive hypothesis is supported by the 
stronger parity association among luminal tumors than basal-like tumors in our study.   
A second parity-associated hypothesis relates to a role for the involuting 
microenvironment in tumor promotion.  Studies demonstrate that during post-lactational 
involution, immune cells infiltrate in breast tissue and the microstructure is remodeled (138, 
254), which may create a permissive environment for breast cancer promotion and progression 
(255).  Interestingly, in a recent gene expression study, we detected a pregnancy-associated 
inflammatory signature among ER-positive breast cancers, but not among ER-negative tumors 
(222).  These findings highlight some parity-associated changes in microenvironment may 
particularly favor ER-positive/luminal tumors.   
Third, the differences in parity-associated breast cancer aggressiveness by subtype may 
reflect fundamental differences in progression patterns between the two cancer types.  Anderson 
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et al. have clearly demonstrated that the hazard rate for mortality is higher for ER-negative than 
for ER-positive breast cancers in the first three years following diagnosis (221).  If hazards are 
uniformly high among ER-negative and/or basal-like breast cancers, then parity may do little to 
alter this course.  However, we also evaluated progression conditional upon five years of 
survival.  The results, showing no significant difference in effect of parity on basal-like 
progression before and after the first five years after diagnosis, suggest that the phenomenon of 
pregnancy-associated breast cancer aggressiveness may be limited to luminal breast cancers.   
Our observation of a specific luminal-promoting effect of parity may seem to contradict 
the high proportion of ER-negative/triple-negative tumors in pregnancy-associated breast cancer 
(256, 257).  However, it is important to distinguish etiologic heterogeneity and subtype-specific 
effects on progression.  While the natural history of tumorigenesis often finds parallels between 
etiologic and progressions factors, it is also often the case that something which lowers barriers 
to carcinogenesis confers no additional advantage once the tumor is formed.   
The mechanisms underlying the association between obesity and breast cancer have been 
well studied, including insulin and insulin-like growth factors, sex hormone, sex steroids, 
adipokines, epithelial-mesenchymal transition, and pro-inflammatory microenvironment (226, 
228, 258).  However, how these mechanisms differentially contribute to the etiology and 
progression of each subtype has not been well characterized.  In general, it is believed that 
increased production of estrogens in the adipose tissue and decreased sex hormone-binding 
globulin are more specific to hormone receptor-positive tumors, while likely other pathways 
work for all subtypes (259).  In our previous study, we have observed infiltration of macrophages 
and up-regulated gene expression of immune response pathways in normal tissues of obese 
women (260).  This pro-inflammatory microenvironment, orchestrated with adipokines, may 
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increase tumor-related angiogenesis and facilitate tumor invasion and metastasis (261, 262).  
This pathway may be particularly important for basal-like tumors, given early blood-borne 
dissemination is more common in this subtype (91).   
In the current research, we detected an association of obesity with overall survival, but not 
BC-specific survival.  The stronger effect of obesity on overall mortality than BC-specific 
mortality has also been observed in previous studies (263, 264).  These findings suggest that 
obesity may influence mortality after breast cancer via tumor-independent mechanisms.  
Obesity-associated comorbidities and obesity-treatment interaction are potentially the key 
contributors to the difference between overall and BC-specific association.  
Based on our analysis, the prognostic influence of obesity on all-cause mortality varied 
not only by subtype, but also by obesity measure.  The different metrics of adiposity has been 
recognized to reflect different underlying characteristics of obesity.  Different adipose tissue 
depots (e.g. visceral and subcutaneous adipose tissues) are different in cellular composition and 
physiology, resulting in their heterogeneous phenotypic properties and roles in disease course 
(241, 242).  Generally visceral/abdominal adipose is considered more metabolically active, and 
plays more important role in pathological status (e.g. chronic inflammation, insulin resistance) 
(241, 242).  These biological differences were mirrored by the results of epidemiological studies, 
where compared with BMI, WHR or waist circumference was more correlated with growth 
hormone, insulin growth factor (IGF)-1, insulin resistance, circulating estradiol fractions and 
leptin (243-245).   While different metrics of adiposity has been intensively studied in etiology of 
diabetes and cardiovascular disease (246-249), unfortunately, it has received limited attention in 
breast cancer studies.  Specific explanations for the different prognostic association by obesity 
measures still need further investigation. 
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6.3. Significance 
The significance of our research is that it addresses several important challenges in 
epidemiology.  First, we are evaluating risk factors for a role in progression, acknowledging that 
some factors may continue to exert effects in the same direction during progression and others 
will not.  Second, we are using anthropometric variables to make inferences about underlying 
biological processes.  Finally, in light of what these data show, priorities for reducing the burden 
of breast cancer can be inferred. 
Parity and obesity are established breast cancer risk factors that have consistently shown 
distinct etiologic associations with intrinsic subtype.  While etiology and progression are 
considered separately in studies, the whole disease course of breast cancer is actually a 
continuous process.  Therefore it is important to consider whether factors that play a role in 
initiation also affect breast cancer progression.  Our results showed that the both parity and 
obesity have effects during progression that are distinct from their effects on etiology.  That is, 
parity reduces risk of luminal breast cancer but increases mortality.  Obesity on the other hand, 
influences breast cancer etiology, but does not appear to strongly influence breast cancer-specific 
survival. 
This research used anthropometric and reproductive factors to investigate critical 
pathways in carcinogenesis.  By comparing the results for obesity and parity, we can infer 
whether each of these interacts with tumor biology or through other mechanisms.  While parity 
significantly influenced BC-specific survival implying an effect on tumor biology, obesity 
showed no relationship with breast cancer specific survival.  Moreover, the effects of parity are 
not mediated solely by established measures of tumor characteristics (e.g. tumor size, lymph 
node status) since this association was independent of these variables.   
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In spite of the limited role for obesity in tumor progression, our data shows that obesity 
remains an important predictor for overall outcome, likely through the pathways not mediated by 
tumor (e.g. host health condition).  These findings are consistent with our early hypotheses.  In 
the section of 3.4 Linkage between risk factors and prognosis, we hypothesized that “obesity 
could influence breast cancer prognosis by altering susceptibility to more aggressive subtypes”, 
therefore “obesity is not associated with breast cancer-specific mortality,” and that parity’s 
“association with breast cancer prognosis is only through breast cancer, without a direct 
pathway”.    
These results of parity and obesity provide important indication for breast cancer 
prevention and management.  Considering parity-prognosis association will be significant to 
optimize treatment and to plan pregnancy in young breast cancer survivors.  Compared with 
parity, obesity-prognosis association has more public health value, since obesity intervention 
reduces risk for both occurrence and mortality.   
6.4. Future directions 
An important future epidemiologic direction is to consider the role of exposures that occur 
after diagnosis. For example, both parity and obesity may interact with treatment (265, 266), 
which may further affects the prognostic association.  Moreover, studies demonstrated weight 
changes after diagnosis due to age, treatment or lifestyle changes, with estimated 50-96% of 
breast cancer patients gaining weight, particularly during chemotherapy (188).  Whether after-
diagnosis weight change varies by subtype and how it influences prognosis cannot be answered 
by our data.  A future study with detailed records on treatment and longitudinal data on parity, 
obesity, and comorbidities will help explain the distinct prognostic associations of parity and 
obesity we observed in this study.   
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Future biological research should focus on well-delineated pathways specific for each 
subtype.  This study is the first one that found that prognostic association of obesity varied by 
both subtype and obesity measures.  This finding needs to be validated in model systems.  BMI 
and WHR are anthropometric measures of general and central obesity respectively.  They reflect 
the difference between visceral and subcutaneous adipose tissue, but cannot accurately capture 
the biological difference.  In order to distinguish the different role by obesity type in breast 
cancer development and progression, studies with more accurate methods measuring different 
type of adiposity and biomarkers describing the different pathways will be critical.  Last, most of 
the obesity-associated biomarkers currently used in large epidemiological studies (e.g. CRP, IL-
6) (238) are originally developed in the settings of cardiovascular disease or diabetes.  Although 
cancer may share some mechanisms with these diseases, more likely obesity and cancer have 
some specific or preferable pathways.  Therefore obesity-associated biomarkers aimed to 
describe the obesity-cancer linkage need further development.   
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APPENDIX A: TABLES 
Table A.1: Characteristics of study population by parity, in the CBCS Phases I and II a. 
Characteristics 
Overall 
(n=1140) 
Nulliparous 
(n=173) 
1-2 
(n=551) 
≥3 
(n=416) 
P-value 
Age (years)      
Mean (SD) 50.64 (12) 49.07 (12.40) 47.91 (10.63) 54.92 (10.98) <0.01 
<40 194 (17) 40 (23) 114 (21) 40 (10) <0.01 
40-49 436 (38) 68 (39) 256 (46) 112 (27)  
50-59 227 (20) 28 (16) 91 (17) 108 (26)  
≥60 283 (25) 37 (21) 90 (16) 156 (38)  
Menopausal status      
Premenopausal 556 (49) 92 (53) 323 (59) 141 (34) <0.01 
Postmenopausal 584 (51) 81 (47) 228 (41) 275 (66)  
Race      
White 622 (55) 99 (57) 348 (63) 175 (42) <0.01 
African American 518 (45) 74 (43) 203 (37) 241 (58)  
BMI (kg/m2)      
Mean (SD) 28.51 (6.89) 27.13 (6.82) 27.83 (6.54) 29.99 (7.14) <0.01 
<25 395 (35) 73 (43) 214 (39) 108 (27) <0.01 
25-<30 308 (28) 44 (26) 160 (29) 104 (26)  
≥30 411 (37) 51 (30) 169 (31) 191 (47)  
WHR      
Mean (SD) 0.82 (0.08) 0.81 (0.08) 0.81 (0.08) 0.84 (0.08) <0.01 
 <0.77 284 (25) 54 (32) 160 (29) 70 (17) <0.01 
0.77-<0.84 389 (35) 53 (31) 206 (38) 130 (32)  
≥0.84 451 (40) 63 (37) 180 (33) 208 (51)  
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Table A.1: Characteristics of study population by parity, in the CBCS Phases I and II a. 
Characteristics 
Overall 
(n=1140) 
Nulliparous 
(n=173) 
1-2 
(n=551) 
≥3 
(n=416) 
P-value 
Years since last full-term pregnancy among parous women     
<5 76 (8) - 58 (11) 18 (4) <0.01 
5-<10 89 (9) - 61 (11) 28 (7)  
≥10 801 (83) - 432 (78) 369 (89)  
Family history of breast cancerb      
Yes 180 (16) 24 (14) 90 (17) 66 (17) 0.75 
No 927 (84) 144 (86) 450 (83) 333 (83)  
Education      
Lower than high school 199 (17) 18 (10) 58 (11) 123 (30) <0.01 
High school/post high school 627 (55) 84 (49) 317 (58) 226 (54)  
College and above 314 (28) 71 (41) 176 (32) 67 (16)  
Family income (thousand US dollar)      
<15 244 (23) 32 (20) 78 (15) 134 (35) <0.01 
15-<30 259 (25) 45 (28) 117 (23) 97 (26)  
30-<50 258 (24) 37 (23) 139 (27) 82 (22)  
≥50 293 (28) 44 (28) 183 (35) 66 (17)  
Smoking      
Never 599 (53) 90 (52) 294 (53) 215 (52) 0.79 
Former 353 (31) 51 (29) 174 (32) 128 (31)  
current 188 (16) 32 (19) 83 (15) 73 (18)  
Alcohol      
No 351 (31) 48 (28) 151 (27) 152 (37) <0.01 
Yes 788 (69) 124 (72) 400 (73) 264 (63)  
Physical activity      
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Table A.1: Characteristics of study population by parity, in the CBCS Phases I and II a. 
Characteristics 
Overall 
(n=1140) 
Nulliparous 
(n=173) 
1-2 
(n=551) 
≥3 
(n=416) 
P-value 
no 560 (49) 81 (47) 262 (48) 217 (52) 0.29 
yes 580 (51) 92 (53) 289 (52) 199 (48)  
HRT      
Never 821 (72) 125 (72) 398 (72) 298 (72) 0.95 
Former 221 (19) 32 (19) 110 (20) 79 (19)  
Current 96 (8) 16 (9) 43 (8) 37 (9)  
OC      
Never 382 (34) 65 (38) 129 (23) 188 (45) <0.01 
Ever 754 (66) 107 (62) 421 (77) 226 (55)  
Lymph node status      
Positive 448 (40) 50 (29) 223 (41) 175 (42) 0.01 
Negative 686 (60) 120 (71) 326 (59) 240 (58)  
Intrinsic subtype      
Luminal 731 (64) 118 (68) 349 (63) 264 (63) 0.58 
Basal-like 205 (18) 24 (14) 109 (20) 72 (17)  
Her2-positive 73 (6) 13 (8) 31 (6) 29 (7)  
Normal-like 131 (11) 18 (10) 62 (11) 51 (12)  
Tumor size (cm)      
<2 540 (48) 84 (49) 251 (47) 205 (50) 0.53 
>2-5 468 (42) 68 (40) 239 (45) 161 (39)  
>5 106 (10) 18 (11) 46 (9) 42 (10)  
Tumor stage (AJCC/UICC Stage Grouping)     
I 414 (37) 69 (41) 193 (36) 152 (38) 0.83 
II 559 (50) 80 (48) 277 (52) 202 (50)  
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Table A.1: Characteristics of study population by parity, in the CBCS Phases I and II a. 
Characteristics 
Overall 
(n=1140) 
Nulliparous 
(n=173) 
1-2 
(n=551) 
≥3 
(n=416) 
P-value 
III+IV 136 (12) 19 (11) 66 (12) 51 (13)  
Histology group      
Ductal 939 (82) 148 (86) 453 (82) 338 (81) 0.46 
Others 201 (18) 25 (14) 98 (18) 78 (19)  
Nuclear gradec      
Pleomorphism 211 (43) 33 (42) 112 (46) 66 (39) 0.43 
Slight/moderate 280 (57) 45 (58) 133 (54) 102 (61)  
Histologic gradec      
Well/moderate 173 (35) 27 (35) 81 (33) 65 (39) 0.50 
Poor 318 (65) 51 (65) 164 (67) 103 (61)  
Mitotic indexc      
Low 265 (54) 44 (56) 130 (54) 91 (54) 0.90 
High 224 (46) 34 (44) 113 (46) 77 (46)  
a P-values for the comparisons across parity groups were calculated by t test for continuous variables and x2 test for categorical variables 
except that when expected cell count was less than 5, they were calculated by Fisher exact test. Missing values were excluded from percentage 
calculations. 
b First degree. 
c Only available in Phase I.   
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Table A.2: Characteristics of study population by last birth recency group, in the CBCS Phases I and IIa. 
Characteristics 
Overall 
(n=1139) 
Nulliparous 
(n=173) 
<5 years 
(n=76) 
5-<10 years 
(n=89) 
≥ 10 years 
(n=801) 
P-value 
Age (years)       
Mean (SD) 50.62 (11.49) 49.07 (12.4) 35.43 (5.03) 39.46 (5.23) 53.64 (10.20) <.01 
<40 194 (17) 40 (23) 59 (78) 44 (49) 51 (6)  
40-49 436 (38) 68 (39) 17 (22) 44 (49) 307 (38)  
50-59 227 (20) 28 (16) 0 (0) 1 (1) 198 (25)  
≥60 282 (25) 37 (21) 0 (0) 0 (0) 245 (31)  
Menopausal status       
Premenopausal 556 (49) 92 (53) 72 (95) 84 (94) 308 (38) <.01 
Postmenopausal 583 (51) 81 (47) 4 (5) 5 (6) 493 (62)  
Race       
White 622 (55) 99 (57) 50 (66) 52 (58) 421 (53) 0.10 
African American 517 (45) 74 (43) 26 (34) 37 (42) 380 (47)  
BMI (kg/m2)       
Mean (SD) 28.51 (6.89) 27.13 (6.82) 26.69 (7.12) 26.91 (6.65) 29.15 (6.82) <.01 
<25 395 (35) 73 (43) 38 (51) 35 (41) 249 (32) <.01 
25-<30 308 (28) 44 (26) 16 (22) 29 (34) 219 (28)  
≥30 411 (37) 51 (30) 20 (27) 22 (26) 318 (40)  
WHR       
Mean (SD) 0.82 (0.08) 0.81 (0.08) 0.79 (0.09) 0.79 (0.07) 0.83 (0.08) <.01 
 <0.77 284 (25) 54 (32) 30 (41) 31 (36) 169 (21) <.01 
0.77-<0.84 389 (35) 53 (31) 28 (38) 33 (38) 275 (35)  
≥0.84 451 (40) 63 (37) 15 (21) 23 (26) 350 (44)  
Full term pregnancy       
nulliparous 173 (15) 173 (100) 0 (0) 0 (0) 0 (0) <.01 
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Table A.2: Characteristics of study population by last birth recency group, in the CBCS Phases I and IIa. 
Characteristics 
Overall 
(n=1139) 
Nulliparous 
(n=173) 
<5 years 
(n=76) 
5-<10 years 
(n=89) 
≥ 10 years 
(n=801) 
P-value 
1-2 551 (48) 0 (0) 58 (76) 61 (69) 432 (54)  
≥ 3 415 (36) 0 (0) 18 (24) 28 (31) 369 (46)  
Family history of breast cancerb      
Yes 180 (16) 24 (14) 10 (14) 10 (11) 136 (18) 0.33 
No 926 (84) 144 (86) 63 (86) 79 (89) 640 (82)  
Education       
Lower than high school 198 (17) 18 (10) 4 (5) 6 (7) 170 (21) <.01 
High school/post high 
school 
627 (55) 84 (49) 35 (46) 45 (51) 463 (58)  
College and above 314 (28) 71 (41) 37 (49) 38 (43) 168 (21)  
Family income (thousand US dollar)      
<15 259 (25) 32 (20) 14 (19) 9 (11) 188 (26) <.01 
15-<30 258 (24) 45 (28) 11 (15) 22 (27) 181 (25)  
30-<50 293 (28) 37 (23) 19 (25) 19 (23) 183 (25)  
≥50 243 (23) 44 (28) 31 (41) 33 (40) 185 (25)  
Smoking       
Never 599 (53) 90 (52) 51  (67) 57 (64) 401 (50) 0.01 
Former 352 (31) 51 (29) 21 (28) 19 (21) 261 (33)  
current 188 (17) 32 (19) 4 (5) 13 (15) 139 (17)  
Alcohol       
No 350 (31) 48 (28) 14 (18) 23 (26) 265 (33) 0.03 
Yes 788 (69) 124 (72) 62 (82) 66 (74) 536 (67)  
Physical activity       
no 559 (49) 81 (47) 40 (53) 41 (46) 397 (50) 0.77 
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Table A.2: Characteristics of study population by last birth recency group, in the CBCS Phases I and IIa. 
Characteristics 
Overall 
(n=1139) 
Nulliparous 
(n=173) 
<5 years 
(n=76) 
5-<10 years 
(n=89) 
≥ 10 years 
(n=801) 
P-value 
yes 580 (51) 92 (53) 36 (47) 48 (54) 404 (50)  
HRT       
Never 820 (72) 125 (72) 74 (97) 83 (93) 538 (67) <.01 
Former 221 (19) 32 (19) 0 (0) 3 (3) 186 (23)  
Current 96 (8) 16 (9) 2 (3) 3 (3) 75 (9)  
OC       
Never 381 (34) 65 (38) 4 (5) 11 (12) 301 (38) <.01 
Ever 754 (66) 107 (62) 72 (95) 78 (88) 497 (62)  
Lymph node status       
Positive 447 (39) 50 (29) 42 (55) 40 (45) 315 (39) <.01 
Negative 686 (61) 120 (71) 34 (45) 49 (55) 483 (61)  
Intrinsic subtype       
Luminal 730 (64) 118 (68) 42 (55) 41 (46) 529 (66) 0.01 
Basal-like 205 (18) 24 (14) 14 (18) 26 (29) 141 (18)  
Her2-positive 73 (6) 13 (8) 7 (9) 7 (8) 46 (6)  
Normal-like 131 (12) 18 (10) 13 (17) 15 (17) 85 (11)  
Tumor size (cm)       
<2 540 (49) 84 (49) 32 (43) 37 (42) 387 (50) 0.72 
>2-5 467 (42) 68 (40) 33 (45) 43 (49) 323 (41)  
>5 106 (10) 18 (11) 9 (12) 8 (9) 71 (9)  
Tumor stage (AJCC/UICC Stage 
Grouping) 
     
I 414 (37) 69 (41) 21 (28) 30 (34) 294 (38) 0.24 
II 558 (50) 80 (48) 39 (53) 51 (58) 388 (50)  
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Table A.2: Characteristics of study population by last birth recency group, in the CBCS Phases I and IIa. 
Characteristics 
Overall 
(n=1139) 
Nulliparous 
(n=173) 
<5 years 
(n=76) 
5-<10 years 
(n=89) 
≥ 10 years 
(n=801) 
P-value 
III+IV 136 (12) 19 (11) 14 (19) 7 (8) 96 (12)  
Histology group       
Ductal 938 (82) 148 (86) 69 (91) 72 (81) 649 (81) 0.11 
Others 201 (18) 25 (14) 7 (9) 17 (19) 152 (19)  
Nuclear gradec       
Pleomorphism 211 (43) 33 (42) 18 (55) 22 (56) 138 (41) 0.14 
Slight/moderate 279 (57) 45 (58) 15 (45) 17 (44) 202 (59)  
Histologic gradec       
Well/moderate 172 (35) 27 (35) 4 (12) 15 (38) 126 (37) 0.04 
Poor 318 (65) 51 (65) 29 (88) 24 (62) 214 (63)  
Mitotic indexc       
Low 264 (54) 44 (56) 13 (39) 17 (44) 190 (56) 0.15 
High 224 (46) 34 (44) 20 (61) 22 (56) 148 (44)  
a P-values for the comparisons across birth recency were calculated by t test for continuous variables and x2 test for categorical variables 
except that when expected cell count was less than 5, they were calculated by Fisher exact test. Missing values were excluded from percentage 
calculations. 
b First degree 
c Only available in Phase I 
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Table A.3: HRs of BC-specific mortality associated with parity and birth recency, in the CBCS 
Phases I and IIa 
  Model 1 Model 2 Model 3 
Variable Deaths/N HR (95%CI) HR (95%CI) HR (95%CI) 
Parity 
All BC patients     
nulliparous 31/173 1.32 (0.89, 1.95) 1.44 (0.94, 2.21) 1.16 (0.76, 1.78) 
1-2 132/551 1.77 (1.18, 2.66) 1.76 (1.13, 2.73) 1.42 (0.91, 2.23) 
3+ 113/416    
Basal-like 
 1 1 1 
nulliparous 6/24 1.05 (0.43, 2.56) 1.28 (0.49, 3.39) 1.44 (0.52, 4.03) 
1-2 30/109 1.52 (0.61, 3.82) 1.56 (0.58, 4.21) 1.45 (0.52, 4.05) 
3+ 26/72    
Luminal 
 1 1 1 
nulliparous 13/118 2.02 (1.12, 3.64) 2.12 (1.14, 3.91) 1.46 (0.78, 2.75) 
1-2 78/349 2.54 (1.38, 4.68) 2.34 (1.22, 4.47) 1.56 (0.81, 3.03) 
3+ 62/264 1.32 (0.89, 1.95) 1.44 (0.94, 2.21) 1.16 (0.76, 1.78) 
Birth recency 
All BC patients     
nulliparous 31/173 1 1 1 
<5 years 28/76 1.83 (1.07, 3.13) 1.90 (1.10, 3.34) 1.37 (0.77. 2.45) 
5-<10 years 27/89 1.42 (0.84, 2.40) 1.45 (0.83, 2.55) 1.09 (0.61, 1.95) 
10+ years 190/801 1.43 (0.97, 2.11) 1.51 (0.99, 2.29) 1.26 (0.82, 1.93) 
Basal-like     
nulliparous 6/24 1 1 1 
<5 years 5/14 1.40 (0.41, 4.72) 1.55 (0.43, 5.56) 1.38 (0.38, 5.08) 
5-<10 years 8/26 1.07 (0.36, 3.21) 1.21 (0.38, 3.89) 0.84 (0.24, 2.89) 
10+ years 43/141 1.22 (0.51, 2.94) 1.41 (0.54, 3.68) 1.69 (0.62, 4.63) 
Luminal     
nulliparous 13/118 1 1 1 
<5 years 18/42 3.66 (1.73, 7.75) 3.78 (1.74, 8.19) 2.35 (1.05, 5.27) 
5-<10 years 14/41 2.91 (1.35, 6.27) 2.84 (1.23, 6.57) 2.10 (0.89, 4.94) 
10+ years 108/529 1.94 (1.08, 3.47) 1.90 (1.03, 3.50) 1.30 (0.69, 2.43) 
a Model 1 was adjusted for age, race, and study phase; model 2 was additionally adjusted for income and 
education; model 3 was additionally adjusted for tumor stage, tumor size, lymph node status, and 
histological type. 
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Table A.4: HRs of all-cause mortality associated with parity and birth recency, in the CBCS 
Phases I and IIa 
  Model 1 Model 2 Model 3 
Variable Deaths/N HR (95%CI) HR (95%CI) HR (95%CI) 
Parity 
All BC patients     
nulliparous 65/173 1 1 1 
1-2 195/551 0.97 (0.73, 1.28) 1.03 (0.76, 1.39) 0.91 (0.67, 1.24) 
3+ 190/416 1.09 (0.82, 1.45) 1.05 (0.77, 1.43) 0.93 (0.67, 1.28) 
Basal-like 
 
   
nulliparous 12/24 1 1 1 
1-2 38/109 0.67 (0.34, 1.30) 0.84 (0.40, 1.68) 0.90 (0.42, 1.94) 
3+ 36/72 0.97 (0.48, 1.94) 0.96 (0.45, 2.03) 0.91 (0.42, 1.99) 
Luminal 
 
   
nulliparous 40/118 1 1 1 
1-2 125/349 1.14 (0.80, 1.63) 1.16 (0.80, 1.69) 0.99 (0.67, 1.46) 
3+ 118/264 1.17 (0.81, 1.69) 1.08 (0.74, 1.60) 0.92 (0.61, 1.39) 
Birth recency 
All BC patients     
nulliparous 65/173 1 1 1 
<5 years 30/76 1.29 (0.81, 2.05) 1.31 (0.81, 2.12) 1.03 (0.63, 1.71) 
5-<10 years 31/89 1.05 (0.68, 1.64) 1.12 (0.70, 1.78) 0.95 (0.58, 1.54) 
10+ years 323/801 0.99 (0.75, 1.29) 1.00 (0.75, 1.33) 0.90 (0.66, 1.22) 
Basal-like     
nulliparous 12/24 1 1 1 
<5 years 6/14 1.00 (0.36, 2.74) 1.06 (0.37, 3.04) 0.98 (0.33, 2.90) 
5-<10 years 8/26 0.64 (0.25, 1.63) 0.76 (0.29, 2.05) 0.57 (0.20, 1.64) 
10+ years 60/141 0.77 (0.40, 1.49) 0.86 (0.42, 1.76) 0.98 (0.47, 2.06) 
Luminal     
nulliparous 40/118 1 1 1 
<5 years 18/42 1.96 (1.07, 3.61) 2.01 (1.07, 3.76) 1.52 (0.79, 2.94) 
5-<10 years 17/41 1.81 (1.00, 3.27) 1.86 (0.97, 3.56) 1.62 (0.83, 3.15) 
10+ years 207/529 1.06 (0.75, 1.49) 1.02 (0.71, 1.46) 0.87 (0.59, 1.28) 
a Model 1 was adjusted for age, race, and study phase; model 2 was additionally adjusted for income and 
education; model 3 was additionally adjusted for tumor stage, tumor size, lymph node status, and 
histological type. 
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Table A.5: HRs of BC-specific mortality associated with parity and birth recency, by follow-up time, in the CBCS Phases I 
and IIa. 
Parity 
HR (95%CI) 
Birth recency 
HR (95%CI) 
≤ 5 years > 5 years ≤ 5 years > 5 years 
All BC patients 
  All BC patients   
nulliparous 1 1 nulliparous 1 1 
1-2 1.22 (0.75, 2.00) 1.49 (0.78, 2.85) <5 years 1.59 (0.81, 3.13) 2.28 (0.99, 5.23) 
3+ 1.43 (0.86, 2.39) 2.41 (1.25, 4.65) 5-<10 years 1.16 (0.58, 2.31) 1.89 (0.84, 4.25) 
   10+ years 1.28 (0.79, 2.08) 1.73 (0.84, 4.25) 
Basal-like   Basal-like   
nulliparous 1 1 nulliparous 1 1 
1-2 1.03 (0.39, 2.72) 1.13 (0.13, 9.71) <5 years 1.64 (0.46, 5.86) - 
3+ 1.28 (0.46, 3.52) 2.90 (0.35, 23.90) 5-<10 years 0.95 (0.28, 3.24) 1.68 (0.15, 18.84) 
   10+ years 1.09 (0.42, 2.85) 1.93 (0.24, 15.24) 
Luminal   Luminal   
nulliparous 1 1 nulliparous 1 1 
1-2 1.47 (0.68, 3.17) 2.91 (0.15, 7.35) <5 years 1.86 (0.63, 5.53) 6.65 (2.29, 19.33) 
3+ 1.60 (0.72, 3.57) 4.08 (1.59, 10.47) 5-<10 years 1.68 (0.54, 5.19) 4.91 (1.63, 14.75) 
   10+ years 1.44 (0.68, 3.05) 2.78 (1.11, 6.96) 
aThe association was adjusted for age, race, and study phase. 
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Table A.6: Characteristics of study population by BMI group, in the CBCS Phases I and IIa. 
Characteristics Overall 
(n=1109) 
<25 kg/m2 
(n=395) 
25-<30 kg/m2 
(n=308) 
30+ kg/m2 
(n=411) 
P-value 
Age (years)      
Mean (SD) 50.60 (11.45) 48.64 (11.72) 51.47 (11.15) 51.82 (11.19) <0.01 
<40 188 (17) 90 (23) 42 (14) 56 (14) <0.01 
40-49 427 (39) 163 (41) 116 (38) 148 (36)  
50-59 220 (20) 56 (14) 68 (22) 96 (23)  
≥60 274 (25) 84 (21) 80 (26) 110 (27)  
Menopausal status     
Premenopausal 541 (49) 209 (53) 138 (45) 194 (47) 0.08 
Postmenopausal 568 (51) 184 (47) 168 (55) 216 (53)  
Race      
White 612 (55) 301 (77) 173 (57) 138 (34) <0.01 
African American 497 (45) 92 (23) 133 (43) 272 (66)  
Number of full-term pregnancy      
Nulliparous 168 (15) 73 (18) 44 (14) 51 (12) <0.01 
1-2 541 (49) 214 (54) 158 (52) 169 (41)  
≥3 400 (36) 106 (27) 104 (34) 190 (46)  
Years since last full-term pregnancy among parous women   
<5 72 (8) 38 (12) 15 (6) 19 (5) <0.01 
5-<10 86 (9) 35 (11) 29 (11) 22 (6)  
≥10 783 (83) 249 (77) 218 (83) 318 (89)  
Family history of breast cancerb     
Yes 176 (16) 57 (15) 50 (17) 69 (17) 0.66 
No 901 (84) 326 (85) 246 (83) 331 (83)  
Education      
Lower than high 
school 
187 (17) 41 (10) 42 (14) 104 (25) <0.01 
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Table A.6: Characteristics of study population by BMI group, in the CBCS Phases I and IIa. 
Characteristics Overall 
(n=1109) 
<25 kg/m2 
(n=395) 
25-<30 kg/m2 
(n=308) 
30+ kg/m2 
(n=411) 
P-value 
High school/post 
high school 
616 (56) 197 (50) 184 (60) 235 (57)  
College and above 306 (28) 155 (39) 80 (26) 71 (17)  
Family income (thousand US dollar)     
<15 235 (23) 65 (18) 56 (20) 114 (29) <0.01 
15-<30 253 (25) 61 (17) 70 (25) 122 (31)  
30-<50 250 (24) 86 (24) 77 (28) 87 (22)  
≥50 291 (28) 152 (42) 73 (26) 66 (17)  
Smoking      
Never 585 (53) 205 (52) 147 (48) 233 (57) 0.11 
Former 345 (31) 117 (30) 107 (35) 121 (29)  
current 184 (17) 73 (18) 54 (18) 57 (14)  
Physical activity      
yes 566 (51) 213 (54) 159 (52) 194 (47) 0.14 
no 543 (49) 180 (46) 147 (48) 216 (53)  
Alcohol 
consumption 
     
No 344 (31) 79 (20) 99 (32) 166 (40) <0.01 
Yes 764 (69) 313 (80) 207 (68) 244 (60)  
HRT      
Never 794 (72) 276 (70) 210 (69) 308 (75) 0.06 
Former 218 (20) 87 (22) 69 (23) 62 (15)  
Current 95 (9) 29 (7) 27 (9) 39 (10)  
OC      
Never 368 (33) 104 (27) 110 (36) 154 (38) <0.01 
Ever 737 (67) 287 (73) 194 (64) 256 (62)  
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Table A.6: Characteristics of study population by BMI group, in the CBCS Phases I and IIa. 
Characteristics Overall 
(n=1109) 
<25 kg/m2 
(n=395) 
25-<30 kg/m2 
(n=308) 
30+ kg/m2 
(n=411) 
P-value 
Lymph node status     
Positive 439 (40) 144 (37) 130 (43) 165 (41) 0.27 
Negative 665 (60) 248 (63) 175 (57) 242 (59)  
Intrinsic subtype      
Luminal 714 (64) 266 (68) 197 (64) 251 (61) 0.02 
Basal-like 197 (18) 53 (13) 61 (20) 83 (20)  
Her2-positive 72 (6) 23 (6) 25 (8) 24 (6)  
Normal-like 126 (11) 51 (13) 23 (8) 52 (13)  
Tumor size (cm)      
<2 526 (49) 205 (54) 141 (47) 180 (45) 0.09 
>2-5 455 (42) 151 (39) 127 (43) 177 (44)  
>5 102 (9) 27 (7) 30 (10) 45 (11)  
Tumor stage (AJCC/UICC Stage Grouping)    
I 403 (37) 157 (41) 116 (39) 130 (33) 0.09 
II 543 (50) 189 (49) 141 (47) 213 (53)  
III+IV 133 (12) 38 (10) 40 (13) 55 (14)  
Histology group      
Ductal 911 (82) 312 (79) 256 (84) 343 (84) 0.21 
Others 198 (18) 81 (21) 50 (16) 67 (16)  
Nuclear gradec      
Pleomorphism 204 (43) 79 (42) 57 (43) 68 (44) 0.93 
Slight/moderate 275 (57) 111 (58) 76 (57) 88 (56)  
Histologic gradec      
Well/moderate 309 (65) 125 (66) 85 (64) 99 (63) 0.89 
Poor 170 (35) 65 (34) 48 (36) 57 (37)  
Mitotic index ǂ      
Low 259 (54) 115 (61) 58 (44) 86 (55) 0.02 
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Table A.6: Characteristics of study population by BMI group, in the CBCS Phases I and IIa. 
Characteristics Overall 
(n=1109) 
<25 kg/m2 
(n=395) 
25-<30 kg/m2 
(n=308) 
30+ kg/m2 
(n=411) 
P-value 
High 218 (46) 75 (39) 73 (56) 70 (45)  
a P values for the comparisons across intrinsic subtypes were calculated by t test for continuous variables and x2 test for categorical variables 
except that when expected cell count was less than 5, they were calculated by Fisher exact test. Missing values were excluded from 
percentage calculations. 
b First degree 
c Only available in Phase I.   
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Table A.7: Characteristics of study population by WHR tertiles, in the CBCS Phases I and IIa. 
Characteristics Overall 
(n=1109) 
<0.77 
(n=282) 
0.77-<0.84 
(n=382) 
0.84+ 
(n=445) 
P-value 
Age (years)      
Mean (SD) 50.60 (11.45) 46.99 (10.46) 50.33 (11.50) 53.75 (11.01) <0.01 
<40 188 (17) 83 (29) 62 (16) 43 (10) <0.01 
40-49 427 (39) 124 (44) 159 (42) 144 (32)  
50-59 220 (20) 36 (13) 70 (18) 114 (26)  
≥60 274 (25) 39 (14) 91 (24) 144 (32)  
Menopausal status      
Premenopausal 541 (49) 180 (64) 197 (52) 164 (37) <0.01 
Postmenopausal 568 (51) 102 (36) 185 (48) 281 (63)  
Race      
White 612 (55) 222 (79) 228 (60) 162 (36) <0.01 
African American 497 (45) 60 (21) 154 (40) 283 (64)  
Number of full-term pregnancy      
Nulliparous 168 (15) 53 (19) 52 (14) 63 (14) <0.01 
1-2 541 (49) 160 (57) 204 (53) 177 (40)  
≥3 400 (36) 69 (24) 126 (33) 205 (46)  
Years since last full-term pregnancy among parous women    
<5 72 (8) 30 (13) 27 (8) 15 (4) <0.01 
5-<10 86 (9) 31 (14) 32 (10) 23 (6)  
≥10 783 (83) 168 (73) 271 (82) 345 (90)  
Family history of breast cancerb     
Yes 176 (16) 239 (86) 318 (83) 356 (82) 0.52 
No 901 (84) 40 (14) 63 (17) 76 (18)  
Education      
Lower than high 
school 
187 (17) 12 (4) 52 (14) 123 (28) <0.01 
  
9
0
 
Table A.7: Characteristics of study population by WHR tertiles, in the CBCS Phases I and IIa. 
Characteristics Overall 
(n=1109) 
<0.77 
(n=282) 
0.77-<0.84 
(n=382) 
0.84+ 
(n=445) 
P-value 
High school/post 
high school 
616 (56) 145 (51) 213 (56) 258 (58)  
College and above 306 (28) 125 (44) 117 (31) 64 (14)  
Family income (thousand US dollar)     
<15 235 (23) 29 (11) 69 (19) 137 (34) <0.01 
15-<30 253 (25) 46 (17) 85 (24) 122 (30)  
30-<50 250 (24) 62 (23) 90 (25) 98 (24)  
≥50 291 (28) 128 (48) 116 (32) 47 (12)  
Smoking      
Never 585 (53) 166 (58) 211 (54) 215 (48) <0.01 
Former 345 (31) 92 (32) 120 (31) 135 (30)  
current 184 (17) 26 (9) 58 (15) 101 (22)  
Alcohol 
consumption 
     
No 344 (31) 52 (18) 123 (32) 169 (38) <0.01 
Yes 764 (69) 230 (82) 258 (68) 276 (62)  
Physical activity      
no 566 (51) 130 (46) 182 (48) 231 (52) 0.25 
yes 543 (49) 152 (54) 200 (52) 214 (48)  
HRT      
Never 794 (72) 208 (74) 267 (70) 319 (72) 0.35 
Former 218 (20) 58 (21) 77 (20) 83 (19)  
Current 95 (9) 16 (6) 37 (10) 42 (9)  
OC      
Never 368 (33) 54 (19) 115 (30) 199 (45) <0.01 
Ever 737 (67) 226 (81) 266 (70) 245 (55)  
  
9
1
 
Table A.7: Characteristics of study population by WHR tertiles, in the CBCS Phases I and IIa. 
Characteristics Overall 
(n=1109) 
<0.77 
(n=282) 
0.77-<0.84 
(n=382) 
0.84+ 
(n=445) 
P-value 
Lymph node status 
Positive 439 (40) 103 (36) 153 (40) 183 (41) 0.45 
Negative 665 (60) 178 (64) 227 (60) 260 (59)  
Intrinsic subtype      
Luminal 714 (64) 199 (71) 236 (62) 279 (63) 0.01 
Basal-like 197 (18) 36 (13) 80 (21) 81 (18)  
Her2-positive 72 (6) 20 (7) 30 (8) 22 (5)  
Normal-like 126 (11) 27 (10) 36 (9) 63 (14)  
Tumor size (cm)      
<2 526 (49) 154 (56) 179 (48) 193 (44) <0.01 
>2-5 455 (42) 107 (39) 158 (42) 190 (44)  
>5 102 (9) 13 (5) 38 (10) 51 (12)  
Tumor stage (AJCC/UICC Stage Grouping)     
I 403 (37) 115 (42) 142 (38) 146 (34) 0.01 
II 543 (50) 139 (51) 188 (50) 216 (50)  
III+IV 133 (12) 20 (7) 45 (12) 68 (16)  
Nuclear gradec      
Pleomorphism 204 (43) 59 (44) 92 (56) 76 (57) 0.72 
Slight/moderate 275 (57) 76 (56) 73 (44) 59 (44)  
Histologic gradec      
Well/moderate 170 (35) 47 (35) 53 (32) 70 (39) 0.39 
Poor 309 (65) 88 (65) 112 (68) 109 (61)  
Histology group      
Ductal 911 (82) 224 (79) 307 (80) 380 (85) 0.07 
Others 198 (18) 58 (21) 75 (20) 65 (15)  
Mitotic indexc      
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Table A.7: Characteristics of study population by WHR tertiles, in the CBCS Phases I and IIa. 
Characteristics Overall 
(n=1109) 
<0.77 
(n=282) 
0.77-<0.84 
(n=382) 
0.84+ 
(n=445) 
P-value 
Low 259 (54) 79 (59) 84 (51) 96 (54) 0.38 
High 218 (46) 55 (41) 81 (49) 82 (46)  
a The cutoff points of tertiles were 0.77 and 0.84 based on WHR distribution of controls of CBCS Phase I&II. P-values for the comparisons 
across intrinsic subtypes were calculated by t test for continuous variables and x2 test for categorical variables except that when expected 
cell count was less than 5, they were calculated by Fisher exact test. Missing values were excluded from percentage calculations. 
b First degree 
c Only available in Phase I.   
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Table A.8: HRs for overall mortality associated with BMI and WHR, in the CBCS Phases I 
and IIa 
  Model 1 Model 2 Model 3 
Variable Deaths/N HR (95%CI) HR (95%CI) HR (95%CI) 
BMI 
All BC patients     
<25 kg/m2 129/395 1 1 1 
25-<30 kg/m2 125/308 1.18 (0.91, 1.51) 1.28 (0.98, 1.68) 1.14 (0.86, 1.50) 
≥30 kg/m2 184/411 1.23 (0.96, 1.57) 1.19 (0.91, 1.55) 1.11 (0.84, 1.45) 
Basal-like 
 
   
<25 kg/m2 16/53 1 1 1 
25-<30 kg/m2 27/62 1.49 (0.79, 2.81) 1.90 (0.93, 3.85) 1.65 (0.79, 3.45) 
≥30 kg/m2 41/83 1.92 (1.04, 3.54) 2.25 (1.14, 4.46) 2.04 (1.01, 4.13) 
Luminal 
 
   
<25 kg/m2 84/268 1 1 1 
25-<30 kg/m2 80/198 1.22 (0.89, 1.67) 1.33 (0.95, 1.85) 1.24 (0.88, 1.74) 
≥30 kg/m2 111/251 1.17 (0.86, 1.61) 1.12 (0.80, 1.57) 1.01 (0.71, 1.44) 
WHR 
All BC patients     
<0.77 79/284 1 1 1 
0.77-<0.84 142/389 1.30 (0.98, 1.72) 1.25 (0.92, 1.68) 1.08 (0.79, 1.47) 
≥0.84 221/451 1.68 (1.27, 2.23) 1.50 (1.11, 2.05) 1.25 (0.91, 1.72) 
Basal-like     
<0.77 13/36 1 1 1 
0.77-<0.84 37/81 1.37 (0.70, 2.65) 1.43 (0.69, 2.93) 1.26 (0.61, 2.62) 
≥0.84 34/83 1.11 (0.56, 2.23) 0.88 (0.40, 1.95) 0.87 (0.39, 1.93) 
Luminal     
<0.77 53/201 1 1 1 
0.77-<0.84 77/240 1.15 (0.81, 1.66) 1.09 (0.74, 1.60) 0.89 (0.60, 1.33) 
≥0.84 148/282 1.97 (1.40, 2.78) 1.75 (1,20, 2.56) 1.33 (0.89, 1.97) 
a Model 1 was adjusted for age, race, and study phase; model 2 was additionally adjusted for income, 
education, physical activity, alcohol intake, smoking, and parity; model 3 was additionally adjusted for 
tumor stage, tumor size, lymph node status, and histological type. 
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Table A.9: HRs for BC-specific mortality associated with BMI and WHR, in the CBCS Phases 
I and IIa 
  Model 1 Model 2 Model 3 
Variable Deaths/N HR (95%CI) HR (95%CI) HR (95%CI) 
BMI 
All BC patients     
<25 kg/m2 84/395 1 1 1 
25-<30 kg/m2 79/308 1.22 (0.89, 1.68) 1.27 (0.91, 1.78) 1.07 (0.76, 1.52) 
≥30 kg/m2 106/411 1.16 (0.85, 1.59) 1.06 (0.75, 1.48) 0.97 (0.68, 1.37) 
Basal-like 
 
   
<25 kg/m2 10/53 1 1 1 
25-<30 kg/m2 20/62 1.93 (0.89, 4.17) 2.03 (0.85, 4.84) 1.40 (0.56, 3.48) 
≥30 kg/m2 30/83 2.06 (0.97, 4.36) 2.21 (0.94, 5.21) 1.67 (0.69, 4.05) 
Luminal 
 
   
<25 kg/m2 53/268 1 1 1 
25-<30 kg/m2 42/198 1.12 (0.74, 1.70) 1.16 (0.74, 1.81) 1.04 (0.66, 1.64) 
≥30 kg/m2 55/251 1.05 (0.69, 1.60) 0.95 (0.60, 1.49) 0.84 (0.52, 1.36) 
WHR 
All BC patients     
<0.77 61/284 1 1 1 
0.77-<0.84 94/389 1.21 (0.87, 1.69) 1.09 (0.77, 1.54) 0.95 (0.66, 1.36) 
≥0.84 118/451 1.37 (0.97, 1.91) 1.14 (0.79, 1.65) 0.91 (0.62, 1.34) 
Basal-like     
<0.77 8/36 1 1 1 
0.77-<0.84 29/81 1.64 (0.73, 3.69) 1.49 (0.64, 3.46) 1.35 (0.58, 3.15) 
≥0.84 24/83 1.25 (0.53, 2.97) 0.98 (0.38, 2.49) 0.94 (0.37, 2.41) 
Luminal     
<0.77 41/201 1 1 1 
0.77-<0.84 44/240 0.98 (0.63, 1.51) 0.92 (0.57, 1.47) 0.75 (0.46, 1.22) 
≥0.84 67/282 1.41 (0.92, 2.17) 1.15 (0.71, 1.85) 0.82 (0.50, 1.36) 
a Model 1 was adjusted for age, race, and study phase; model 2 was additionally adjusted for income, 
education, physical activity, alcohol intake, smoking, and parity; model 3 was additionally adjusted for 
tumor stage, tumor size, lymph node status, and histological type. 
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Table A.10: HRs of overall deaths associated with BMI and WHR, by follow-up time, in the CBCS Phases I and IIa. 
BMI 
HR (95%CI) 
WHR 
HR (95%CI) 
≤ 5 years > 5 years ≤ 5 years > 5 years 
All BC patients 
  All BC patients   
<25 kg/m2  1 1 ≥ 0.77 1 1 
25-<30 kg/m2 1.04 (0.72, 1.50) 1.25 (0.90, 1.72) 0.77-<0.84 1.27 (0.85, 1.89) 1.20 (0.83, 1.73) 
≥30 kg/m2 1.11 (0.62, 1.44) 1.28 (0.94, 1.74) ≥0.84 1.34 (0.91, 1.98) 1.82 (1.29, 2.58) 
Basal-like   Basal-like   
<25 kg/m2  1 1 ≥ 0.77 1 1 
25-<30 kg/m2 1.22 (0.59, 2.53) 2.10 (0.71, 6.23) 0.77-<0.84 1.23 (0.58, 2.62) 1.49 (0.52, 4.26) 
≥30 kg/m2 1.44 (0.72, 2.87) 3.15 (1.13, 8.79) ≥0.84 0.95 (0.43, 2.08) 1.31 (0.45, 3.80) 
Luminal   Luminal   
<25 kg/m2  1 1 ≥ 0.77 1 1 
25-<30 kg/m2 1.13 (0.67, 1.90) 1.21 (0.83, 1.75) 0.77-<0.84 0.94 (0.52, 1.73) 1.18 (0.77, 1.79) 
≥30 kg/m2 1.07 (0.65, 1.74) 1.15 (0.80, 1.66) ≥0.84 1.63 (0.96, 2.78) 1.98 (1.33, 2.94) 
a The association was adjusted for age, race, and study phase. 
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APPENDIX B: FIGURES 
Figure B.1: Overall survival by parity and birth recency, overall, among luminal tumors, and among basal- tumors.  
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Figure B.2: BC-specific survival by parity and last birth recency, overall, among luminal tumors, and among basal- tumors.  
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Figure B.3: BC-specific survival by multiparity-recency groups, in the CBCS Phases I and II.  
 
 
 HRs of BC-specific mortality associated with parity and birth recencya. 
Nulliparous (reference, HR=1) 1-2 3+ 
HRs  regardless 
parity 
Time since last birth ≥10 years 1.42 (0.92, 2.21) 1.47 (0.87, 2.50)  1.51 (1.00, 2.30) 
Time since last birth <10 years 1.69 (1.06, 2.67) 2.02 (1.09, 3.73)  1.65 (1.01, 2.68) 
HRs  regardless recency 1.44 (0.94, 2.19) 1.76 (1.13, 2.73)  
  aHRs were adjusted for age, race, study phase, income and education  
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Figure B.4: HRs of overall and BC-specific death associated with variables of parity-
breastfeeding and last birth-breastfeeding, respectively.  
 
 
 
HRs were adjusted for age, race, study phase, and SES factors. 
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Figure B.5: HRs of overall and BC-specific deaths associated with parity and last birth, by race 
and menopausal status, in patients with luminal and basal-like tumors respectively. 
 
 
 
The HRs were adjusted for age, race (in associations by menopausal status only), study 
phase, and SES factors. 
 
 
 
 
 
 
A. Association by race 
B. Association by menopausal status 
Overall survival 
BC-specific survival 
BC-specific survival 
Overall survival 
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Figure B.6: Overall survival by BMI and WHR, overall, among luminal tumors, and among basal- tumors.  
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Figure B.7: BC-specific survival by BMI and WHR, overall, among luminal tumors, and among basal- tumors.  
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Figure B.8: HRs of overall and BC-specific deaths associated with parity and birth recency, by 
race and menopausal status, in patients with luminal and basal-like tumors respectively. 
 
 
 
 
 
The HRs were adjusted for age, race (in associations by menopausal status only), study 
phase, and SES factors.
A. Association by race 
Overall survival 
BC-specific survival 
B. Association by menopausal status 
Overall survival 
BC-specific survival 
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